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 Protein phosphorylation occurs through enzymatic transfer of the γ-phosphate of 
adenosine triphosphate (ATP) to the hydroxyl moieties of the amino acid residues serine, 
threonine, and tyrosine. This post-translational modification is catalyzed by a group of enzymes 
classified as protein kinases. The phosphotransfer event initiates signal transduction cascades 
that are instrumental in the regulation of diverse cell functions. Aberrant protein kinase activity 
has been associated with various disease states. Because of this, academic as well as 
pharmaceutical efforts have been aimed at the understanding of kinase activity and 
understanding the related disease states. The work described herein focuses specifically on the 
development and evaluation of protein tyrosine kinase inhibitors in hopes to glean further 
knowledge regarding the substrate-binding region of the protein tyrosine kinase, c-Src.
 Chapter 2 will discuss the use of a privileged scaffold, the biphenyl moiety, to screen for 
potential substrate-competitive inhibitors of the protein tyrosine kinase, c-Src. A 300 member 
library of biphenyl-containing compounds was synthesized and evaluated. From this study one 
compound, BiPH 65, emerged as a low micromolar affinity, substrate-competitive inhibitor of c-
Src (IC50: 60.4 micromolar). Thorough evaluation of the compound revealed inhibitory activity 
not only against the kinase domain of the protein, but also against the physiologically relevant 
three domain c-Src (IC50: 17.2 micromolar), as well as the clinically relevant T338M c-Src (IC50: 
26.4 micromolar).  Chapter 3 examines the use of an inhibitor peptide to arrive at truncated, 
xviii 
 
tetrafluorinated peptidomimetic small molecule inhibitors of c-Src. Although initially promising, 
these compounds were eventually found to bind competitively with ATP. Lastly, Chapter 4 
details the study performed using a purchased fragment library. This fragment library was 
screened with hopes to elucidate a new scaffold on which to further optimize and design 
substrate-competitive inhibitors. However, we were happily surprised to find a compound that 
data suggest binds allosterically to the protein tyrosine kinase, c-Src. Although the lead 
compound, [1], does not inhibit cell growth of a human colon carcinoma cell line, compound 
[1c], the methyl ester analog of [1], inhibits cell growth of a human breast cancer cell line (GI50: 





1.1: Kinase Background 
 The regulation of cellular processes is critical for sustaining life. This occurs on a 
biochemical level through the processing of intracellular signals. These signals are interpreted 
by various proteins that can be switched from an on or active state to an off or inactive state 
depending on cellular environmental stimuli including changes in substrate concentration. 
Through fluctuations in enzymatic conformations, cellular processes such as cell growth, 
differentiation and proliferation are modulated. The processing of cellular signals occurs at a 
cost of a supply of energy. This energy supply is conserved through events such as the 
hydrolysis of nucleoside triphosphates like ATP and GTP. Since cellular activities can be likened 
to a system of checks and balances, every signaling event is paired with an energy providing 
biochemical reaction and is observed through post-translational modifications of the signaling 
protein.1 
 Post-translational modifications are reversible reactions that are catalyzed by enzymes. 
The most prevalent post-translational modification is reversible phosphorylation as it affects 
one-third of cellular proteins.1 A majority of signal transduction pathways are involved with a 
phosphotransfer cascade.2 Protein phosphorylation is catalyzed by a class of enzymes known as 
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protein kinases. These enzymes facilitate the transfer of the γ-phosphate of adenosine 
triphosphate (ATP) to the hydroxyl moieties of amino acid residues, serine, threonine and 
tyrosine of the natural peptide substrate.1,3,4 (Figure 1.1) The protein kinase reaction occurs as 
the two substrates, ATP and a protein, bind to the catalytic domain of the kinase. Following the 
transfer of the γ-phosphate from ATP to the protein substrate, the phosphorylated product and 
ADP are released.5 This phosphotransfer thus initiates signaling cascades that regulate cell 
functions such as cell growth, differentiation, proliferation, angiogenesis, metabolism, and 
apoptosis.3-7 The kinase domain not only binds the protein substrate, but also binds 
magnesium, a cofactor.5 
 
 
1.1.1: Kinase Families  
The human kinome encompasses both lipid kinases as well as protein kinases.5 The 
protein kinase superfamily consists of 518 individual kinases and comprises 1.7% of genes in the 
human genome.1,2,5,7 Most protein kinases (478) contain an eukaryotic protein kinase (ePK) 
catalytic domain, whereas the other 40 kinases lack this conserved catalytic domain and are 
Figure 1.1: The reversible phosphorylation reaction facilitated by a protein kinase and a protein 
phosphatase. Adapted from Marks, et. al. 2009. 
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regarded as atypical protein kinases (aPK).5,7 Eight principle sub-families define the protein 
kinase superfamily. They include the tyrosine kinases (TK), tyrosine kinase-like (TKL), STE20 
STE11 STE7 related (STE), casein kinase 1 (CK1), protein kinase A, protein kinase G and protein 
kinase C related (AGC), Ca2+/calmodulin-dependent kinases (CAMK), Cdk MAPK GSK and Cdk-
like related (CMGC), and finally receptor guanylyl cyclase (RGC).3,5,7 Regarding cellular protein 
bound phosphoamino acids, approximately 95% exist as phosphoserine, 5% exist as 
phosphothreonine, while only 0.01-0.1% is found as phosphotyrosine.3,8 More generally, 
protein kinases can phosphorylate either serine/threonine residues or tyrosine residues. Only 
90 out of the 518 known kinases are capable of phosphorylating tyrosine residues.9 Although 
small in number, this sub-family of protein tyrosine kinases (PTKs) is instrumental in many 
diverse cellular regulatory functions.3,4,10 In addition to the regulation of cell growth, 
differentiation and development, cell survival and apoptosis, transcriptional regulation and 
glucose uptake, PTKs control T-cell and B-cell activation, as well as extracellular stimuli 
response, mitogenesis, angiogenesis, oncogenesis, platelet activation, cell shape and 
attachment, and lastly, neurotransmitter signaling.3,4,10  
1.1.2: The Protein Tyrosine Kinase Family 
The PTK family can be further divided into two smaller sub-classes: receptor protein 
tyrosine kinases (RPTK) and non-receptor (cytosolic) protein tyrosine kinases (NPTK). RPTKs are 
transmembrane proteins with inherent PTK catalytic activity. The N-terminus of a RPTK resides 
outside the confines of the cell and serves as the ligand binding domain, while the cytoplasmic 
domain contains a protein kinase catalytic domain.5,11-13 RPTKs main function is to transduce a 
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signal from the extracellular binding of a ligand into the cytoplasm of the cell.12 Examples of 
RPTKs include the insulin receptor (IR) and the human epidermal growth factor receptor family 
(HER/EGFR).5 However, the NPTK sub-class of PTKs are more diverse as they not only are 
cytoplasmic proteins, but also membrane-associated as well as nuclear proteins.12 There are 10 
NPTK families14, ABL15,16, ACK17, CSK18,19, FAK20-23, FES24,25, FRK26-29, JAK30-33, SRC34-38, TEC39-42, 
and SYK43,44. The scope of this work focuses solely on the NPTK family of kinases and most 
specifically on the SRC family of protein tyrosine kinases as their implication in disease states is 
not only interesting, but not entirely understood. Our work aims to elucidate a better 
understanding of the NPTK, c-Src.  
1.1.3: The Src Family of NPTKs  
 The Src family is further segregated into two subfamilies, A and B. The Src-A family 
consists of FGR, FYN, SRC, and YES1 while the Src-B family consists of BLK, HCK, LCK, and 





A myristoylation sequence is situated at the N-terminal of the kinase that is attached to a SH4 
domain. A unique domain is connected to the SH3 domain followed by a SH2 domain. By means 
of a linker region, the SH2 domain is appended to the SH1 domain. The SH1 domain is the 
Figure 1.2: A schematic of the structural components of the SRC family kinases. Adapted from 
Finn, 2008, Sen, 2011 and Roskoski, 2004. 



















catalytic tyrosine kinase domain. Lastly, a C-terminal regulatory segment is found following the 
SH1 domain.46  
 Membrane association of the kinase is facilitated by the myristoylation of the N-
terminus of the kinase. This modification of the kinase aids in attachment and localization to 
the plasma membrane.8,46-50 The first amino acid of the N-terminal tail, methionine 1, is 
removed and glycine 2 is myristoylated increasing the hydrophobicity of the N-terminal tail and 
aiding in the attachment to the membrane.8 Furthermore, the SH4 domain serves to regulate 
cellular management of other different Src family kinases in the cell.46 The unique domain of 
the kinase structure is not conserved throughout the family members and imparts distinctive 
properties to each kinase.8,46  
Both the SH3 and SH2 domains are involved with regulation of protein-protein 
interactions.51 The SH3 domain consists of approximately 60 amino acid residues that 
characteristically bind to proline-rich sequences allowing for interactions between substrate 
and enzyme as well as other intramolecular reactions.8,46,48,52 The slightly larger SH2 domain 
(approximately 100 amino acids) binds to phosphorylated tyrosine residues either on the 
regulatory C-terminal tail or those of other protein sequences that the particular kinase has 
preference.46  The preferred ligand binding motif of Src family PTKs is pY-E-E-I.4,8,47 Tyr 530 
resides on the C-terminal tail; when this residue is phosphorylated, it is bound to the SH2 
domain of the kinase rendering the kinase in the inactive form. When this residue becomes 
unphosphorylated and Tyr 419 of the SH1 domain is phosphorylated, the kinase is said to be in 
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the active conformation.46 Figure 1.3 illustrates the interactions of the various domains of the 
kinase in both the inactive and active forms of the src family kinases.47 
 
 
 The catalytic tyrosine kinase domain or SH1 domain is bi-lobed in structure and contains 
approximately 250 amino acid residues. The smaller N-terminal lobe (approximately 70 amino 
acids) principally aids in the binding of ATP by the use of a glycine-rich loop to coordinate the 
phosphate groups of ATP.47,53 Structurally, the N-terminal lobe consists of a five stranded β-
sheet and an α-helix.53 ATP binds in a pocket formed between the two lobes and makes critical 
hydrogen bonds with the so called hinge region.53 Primarily α-helical, the larger C-terminal lobe 
consists of approximately 180 amino acid residues.47,53 The C-terminal lobe is responsible for 
Figure 1.3: An illustration of the structural domains of the SRC family kinases in the inactive 
and active conformations. Adapted from Roskoski, 2004. 
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the binding of the protein substrate.47 This is due to the activation loop with two conserved 
sequences, Asp-Phe-Gly (or DFG) as well as Ala-Pro-Glu (or APE). Through the coordination of 
magnesium ions, the aspartate residue allows the substrate to interact with the phosphate 
groups of ATP.53 The movement of both lobes allows for the binding of ATP and the release of 
ADP. Furthermore, the movement of the activation loop is instrumental in generating the 
inactive and active conformations of the kinase. When the DFG sequence is in a closed 
conformation, facing into the kinase, the kinase is said to be in the active form. Conversely, 
when the DFG sequence is in an open conformation, or out, the kinase is in an inactive 
conformation.53,54  
1.2: Kinases and Disease 
Initially discovered by Peyton Rous in 1911 due to his studies of viruses, src is regarded 
as the oldest known oncogene.45,55 In 1976, the SRC gene was defined as the first proto-
oncogene and later in 1980, c-Src protein was identified as the first protein tyrosine kinase.48,55 
c-Src assumes an integral role in the regulation of important cellular processes such as survival, 






Activated by cytosolic proteins such as focal adhesion kinase (FAK) or Crk-associated 
substrate (CAS), as well as the dephosphorylation of Tyr 530 and phosphorylation of Tyr 419, 
Src interacts with substrates and downstream signaling molecules.45 As shown in Figure 1.4, Src 
directly affects PI3K, STAT3 and FAK resulting in the onset of diverse cellular processes. 
Although not directly activated by Src, the Ras/Raf pathway, MAPK and cell proliferation are 
regulated by c-Src.45  
The overexpression, the enhancement of kinase catalytic efficiency as well as the 
dysregulation of protein kinases have been found to be instrumental in the onset of disease 
states. This is due to abnormal levels of protein kinase reaction products in the cell.56 Aberrant 
protein kinase activity has been correlated with a multitude of diseases including: cancer, 
rheumatoid arthritis, cardiovascular disease and neurodegenerative disease.10 c-Src has been 
found over-expressed in specific cancers that include: breast, colon, pancreatic, and 
ovarian.45,55,57 In spite of these facts, c-Src has yet to be shown as a central oncogene in human 
Figure 1.4: The physiological roles of c-Src. Adapted from Finn, 2008. 
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cancers, though it is thought that the interruption of the Src signaling cascade could disrupt 
oncogenic pathways.45 Furthermore, increased c-Src concentration alone has not been directly 
reported, however, the increase of c-Src concentration aids greatly in the increased signaling 
between pathways.45  
Because of this, inhibiting c-Src activation may lead to the delay of disease progression 
or prevent the reoccurrence of the disease state.45 One such example rests with HER2-positive 
breast cancer. The HER2 oncogene has not only been correlated to being overexpressed in 20% 
of human breast cancers but also has been associated with reduced patient survival. 
Trastuzumab (Herceptin) treatment is often used to treat HER2-positive breast cancer patients. 
However, these patients eventually tend to develop resistance to the Trastuzumab (Herceptin) 
treatment. Through thorough study, Zhang and coworkers have suggested that the subsequent 
downstream activation of c-Src is the reason for the drug resistance.58,59 With hopes to combat 
such resistance, the inhibition of c-Src has been explored and may have clinical success to the 
benefit of HER2-positive breast cancer patients.58,59 Additionally, c-Src has been associated with 
tamoxifen resistance.59 
1.3: Inhibition of Kinases 
 Because of their role in cellular regulation, protein kinases have been intensely studied 
not only by academia, but thirty percent of pharmaceutical efforts have been extended for the 
study and development of protein kinase inhibitors. This only falls second to G-protein-coupled 
receptor research targets.13,60-65 Hiroyoshi Hidaka developed the first protein kinase inhibitors 
in the 1980s. These inhibitors were naphthalene sulphonamides that had been previously 
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developed for a different target, calmodulin.66 When the naphthalene moiety was replaced 
with an isoquinoline, they no longer affected calmodulin, but instead were inhibitors of protein 
kinases. One of these inhibitors, H8, is shown in Figure 1.5.66 Difficulty with these inhibitors was 
noted as the compounds were of low potency and nonselective. 
 
 
1.3.1: Current Approved Inhibitors of Protein Kinases 
 To date, there are over 130 inhibitors of protein kinases at various stages of clinical 
development and trials.62,63 Despite the amount of effort and time dedicated to protein kinases, 
the U.S. Food and Drug Administration (FDA) has only approved a total of eleven kinase 
inhibitors for use as therapeutics.63 (Table 1.1) All approved therapeutics bind the kinase in an 









Inhibitor Kinase Target 
Imatinib ABL1-2, PDGFR, KIT 
Gefitinib EGFR 
Erlotinib EGFR 
Lapatinib EGFR, ERBB2 
Dasatinib ABL1-2, PDGFR, KIT, SRC 
Nilotinib ABL1-2, PDGFR, KIT 
Sunitinib VEGFR1-3, KIT, PDGFR, RET, CSF1R, FLT3 
Sorafenib VEGFR2, KIT, PDGFR, FLT3, BRAF 
Pazopanib VEGFR1-3, KIT, PDGFR 
Everolimus mTOR 
Temsirolimus mTOR 




1.4: Types of Kinase Inhibition 
 The characterization of protein kinase inhibitors is broadly defined by the mode of 
binding between the inhibitor and the kinase target.67,68 Current inhibitor research and 
development can be organized into various sub-types of protein kinase inhibitors. Each 
inhibitor type affects the kinase in a unique manner and has its own benefits and 
disadvantages. Often, selectivity, potency and lack of structural knowledge are challenging 
obstacles to overcome in inhibitor design. 
1.4.1: Type I and II Inhibitors 
 Protein kinase inhibitors that bind to the ATP binding pocket and compete directly with 
ATP concentrations are classified as Type I or Type II protein kinase inhibitors. Type I kinase 
inhibitors bind to the active conformation of the kinase, when the DFG motif is in the “in” 




position. Type I inhibitors interact with the hinge region of the protein kinase and are capable 
of making the same interactions as ATP with the kinase.62 In contrast, Type II inhibitors are said 
to trap the inactive conformation of the protein kinase, when the activation loop DFG motif is in 
an “out” position.68 Type II inhibitors bind not only to the ATP pocket, but also extend into the 
hydrophobic pocket that is created by the “out” position of the DFG motif.62 
 ATP competitive inhibitors often are extremely potent and successful in clinical studies 
as all FDA approved kinase inhibitors are either classified as Type I or Type II inhibitors. 
However, the ATP binding pocket of protein kinases is highly conserved.69 Because this pocket 
singularly serves to bind a molecule of ATP, these inhibitors often suffer from a lack of 
selectivity. Additionally, in a cancer cell, the cellular concentrations of ATP can be as high as 10 
mM; a concentration much higher than the KM of ATP for the protein kinase. This high ATP 
concentration ultimately dictates that the ATP-competitive inhibitor must be very potent in 
order to compete against such high levels of ATP.60,65,68  
 Although their Type I counterparts are known to lack selectivity, Type II inhibitors gain 
some selectivity from their role in binding to the hydrophobic pocket created by the DFG “out” 
conformation, as they prevent the kinase from adapting the active conformation.62,68 Both 
imatinib and sorafenib are regarded as Type II inhibitors.68 
 Both Type I and Type II inhibitors are affected by mutations within the ATP binding 
pocket. One clinically relevant mutation is that of the gatekeeper residue. This residue resides 
in a hydrophobic pocket in the back of the ATP pocket. When this residue is mutated, from a 
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threonine to a larger hydrophobic residue, access to the pocket is restricted often resulting in 
resistance to the inhibitor.68 
1.4.2: Type III Inhibitors 
 With push to develop equally as potent yet more selective inhibitors than the Type I and 
Type II counterparts, Type III protein kinase inhibitors emerged with the discovery of the highly 
potent and selective MEK inhibitor, PD318088.62,68 Furthermore, Rauh and co-workers have 
discovered other Type III inhibitors fortuitously through in vitro library screens.68,70 Like Type II 
inhibitors, Type III inhibitors stabilize an inactive conformation of the protein kinase by binding 
to the hydrophobic pocket formed by the DFG “out” conformation but not extending into the 
hinge region as Type II inhibitors characteristically do.68 Uniquely, Type III inhibitors stabilize an 
inactive form of the kinase in which the hinge region is in a closed, active conformation but an 
essential glutamate residue is skewed in such a way that catalysis cannot occur.68 
1.4.3: Substrate-Competitive Inhibitors 
 Substrate-competitive inhibitors characteristically probe the substrate binding region of 
protein kinases. The substrate-binding pockets of kinases, are, in general, less conserved than 
the ATP-binding pockets of protein kinases. A small number of natural substrate peptides or 
proteins with unique sequences bind selectively to various kinases. Because of this, it is 
hypothesized that probing the substrate pocket for the design and development of substrate-
competitive inhibitor compounds would yield compounds that have a high specificity for the 
desired kinase target, resulting in a more selective probe or therapeutic. Since natural peptide 
or protein substrates often exist in the cell at concentrations at or below their KM, these types 
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of inhibitors need not have the extreme potency that ATP-competitive inhibitors (Type I and II) 
must possess.3,66,71,72 
 The development of substrate-competitive inhibitors presents a variety of challenges as 
there is a significant lack of structural data for many protein kinases. Therefore, the rational 
design of such inhibitors is difficult. Furthermore, in addition to only being able to achieve low 
micromolar affinities for the kinase target, the substrate pocket is often shallow and solvent 
exposed further hindering any rational design.68 See chapters 2, 3 and 4 for a discussion of work 
in this area.  
1.4.4: Type IV Inhibitors – Allosteric Inhibitors 
Type IV inhibitors are regarded as purely allosteric in nature. Such compounds target 
regions of the kinase apart from the ATP binding pocket and active site.62,68 Truly allosteric 
inhibitors have been elucidated for protein kinases such as Akt as well as Plk1.62 Additionally, 
the compound GNF-2, developed by Nathanael Gray and coworkers, has been described as an 







1.4.5: Type V Inhibitors 
 Divided into two subgroups, Type V inhibitors aim to combine the high affinity 
properties of some inhibitors with the high selectivity properties of others by combining the 
two different compounds to produce one compound with desirable qualities. These compounds 
target two distinct regions of the protein kinase and are known as bisubstrate (Type Va) or 
bivalent (Type Vb).62  
 Type Va bisubstrate inhibitors target both the ATP binding region as well as the 
substrate binding region concurrently.62,76,77 More generally, Type Vb bivalent inhibitors target 
any arrangement of regions of the protein kinase.62,68 Type V inhibitors as a whole aim to 
garner optimal selectivity and potency using the knowledge gleaned from various Type I-IV 
inhibitors and their kinase targets.62,68 
 
Figure 1.6: The structure of the allosteric c-Abl, c-Arg inhibitor, GNF-2. 
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1.5: Scope of the work to be presented 
 The work presented in this dissertation aims to explore the development and evaluation 
of substrate-competitive inhibitors of the protein tyrosine kinase c-Src. In order to accomplish 
this study, various approaches were considered and utilized. To begin with, chapter 2 discusses 
how a privileged scaffold was exploited to design a library of 300 compounds containing a 
biphenyl moiety. This library screen resulted in the discovery of a substrate-competitive c-Src 
inhibitor. Additionally, chapter 2 outlines the use of a specialized TR-FRET screen developed in 
our laboratory to efficiently characterize substrate-competitive inhibitors. Secondly, chapter 3 
describes how we delved into the design of an inhibitor from an inhibitor peptide. Through 
truncation of the parent peptide, we arrived at a peptidomimetic compound that unfortunately 
did not bind in the desired substrate-competitive mode. Lastly, chapter 4 explores the results 
from our study on the use of a fragment library supplied by the Maybridge Chemical Company, 
and how we were able to elucidate a fragment that binds to c-Src in an allosteric manner.  
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The Biphenyl as a Privileged Scaffold 
2.1: Abstract  
Protein tyrosine kinases (PTKs) have been implicated in diseases including cancer, 
inflammation, and diabetes.1 All FDA approved therapeutics targeting PTKs are ATP-competitive 
inhibitors.2,3 Although these inhibitors are extremely potent, the ATP-binding pockets of protein 
kinases share a high sequence similarity and therefore, selectivity is difficult to achieve.4 We 
hypothesize that substrate-competitive inhibition of PTKs can offer advantages over ATP-
competitive inhibition, such as improved selectivity through the more highly conserved 
substrate-binding pocket as well as the ability to address the clinically relevant ATP-binding 
pocket mutations. Thus, we aim to develop small molecule, substrate-competitive PTK 
inhibitors.  
The biphenyl framework was chosen for its ability to mimic protein-protein interactions 
as well as its characteristic binding promiscuity.5-7 Thus, a library of approximately 300 
biphenylethylacetimides, and other compounds similar in structure was screened against wild 
type c-Src (kinase domain and 3-domain) as well as the c-Src gatekeeper T338M mutant. The 
average molecular weight of the compounds within the library was 365.8. This study resulted in 
one compound of great interest, (4-morpholino)biphenylethylacetimide, as it inhibited kinase 
domain c-Src with an IC50 of 52 μM and 3-domain c-Src with an IC50 of 16 μM. Most notably, the 
lead compound inhibited the gatekeeper c-Src T338M mutant with an IC50 of 26 μM. 
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Additionally, Lineweaver-Burke plot analysis suggests that the lead compound binds in the 
desired ATP-noncompetitive, substrate-competitive mode.  
2.2: Introduction 
 Over 500 different enzymes construct the general class known as protein kinases. 
Protein tyrosine kinases (PTKs) represent a small group of kinases within the kinome. 
Functionally, these 90 kinases facilitate the transfer of the γ-phosphate of an adenosine 
triphosphate molecule to its substrate’s phenolic tyrosine residue resulting in the initiation of 
signaling cascades imperative for cell functions such as cell growth, cell division, and 
apoptosis.8,9 Dysregulation of such cellular events results in various disease states including 
cancer, rheumatoid arthritis, cardiovascular disease, as well as neurodegenerative disease.1 
Second only to G-protein coupled receptors, PTKs are a superfamily of intensely investigated 
enzymes. Thirty percent of pharmaceutical research efforts are directed toward the discovery 
of inhibitors of protein kinases.10-14 Of the 90 known PTKs, our interest lies with the non-
receptor PTK c-Src as it regulates diverse cellular processes involving: survival, angiogenesis, 
motility, migration and invasion, as well as cell proliferation. As the first proto-oncogene 
discovered, it is known to be over-expressed in cancers such as breast, colon, pancreatic and 
ovarian.15,16 Over-expressed in 20% of human breast cancers, HER2-positive patients have been 
found to have or eventually develop trastuzumab resistance during treatment. Zhang and 
coworkers suggest that the subsequent downstream activation of c-Src is a result of drug 
resistance. Therefore, to combat this resistance, inhibition of c-Src may have clinical success 
and benefit in HER2-positive breast cancer patients.17,18 
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 Although the importance of therapeutic design is imperative to combat current cancer 
threats, the design of selective, small molecule inhibitors is paramount for the further 
understanding of enzymatic activity. Off-target binding of inhibitors often leads to negative 
effects and toxicity.19 These selective, small molecules act as specific kinase probes that 
investigate the modes of binding and kinase activity that may not be completely understood at 
this time as well as to thwart the incidence of toxic effects due to off-target binding. In the end, 
these molecules may also aid in the rational design of later therapeutics. Selectivity allows for 
the more precise study of the kinase in question as well as its role in various signal transduction 
pathways.  
 Probing the activity of PTKs involves the prevention of the phosphate transfer from ATP 
to kinase substrate. Current approaches include ATP-competition as well as substrate-
competition among others. To date, all FDA approved PTK inhibitors are ATP-competitive in 
nature. Thus, the inhibitor in question must out-compete high concentrations of cellular ATP to 
bind to the dysregulated kinase halting kinase activity.12 This class of compounds, although 
highly potent and successful in clinical studies, suffers from a lack of selectivity amongst the 
more than 500 kinase family members. Low selectivity results from the highly conserved ATP-
binding pocket of kinases.4 This pocket, formed in each kinase, singularly serves to bind a 
molecule of ATP. High pocket conservation renders ATP-competitive inhibitors quite 
promiscuous, as they can bind to their target kinase as well as many other kinases downstream. 
Off-target binding plays a major role in the toxicity of the inhibitors.13,19-21  
Another mode of inhibition currently under investigation rests upon out-competing the 
substrate peptide or protein that would in turn undergo phosphorylation by the abundance of 
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ATP in cancerous cells.13,21 The substrate-binding pockets of kinases are, in general, less 
conserved than the ATP-binding pockets of fellow kinase family members as they bind a small 
number of substrate peptides with unique sequences.8,13,21-23 This characteristic of the 
substrate-binding pocket is hypothesized to provide optimized specificity for desired kinase 
targets and therefore, better therapeutics. Additionally, the inhibitor does not compete with 
high concentrations of substrate peptide, as the substrate peptides exist in much lower 
concentrations than ATP in cancerous cells.8,23 
 Although substrate-competitive inhibitors have tremendous potential, their 
development presents many challenges. Currently, no structural data exists for many PTKs. Lack 
of structural understanding hinders the rational design of such inhibitors, as not much is known 
about the often shallow and solvent exposed substrate-binding pocket. Furthermore, substrate-
competitive inhibitors historically achieve only micromolar affinities for the kinase.8,13,21,23 
Through rational design and the use of a privileged scaffold, we designed, synthesized and 
evaluated a series of inhibitors containing a biphenyl side chain showing great potential in the 
development of an optimized substrate-competitive c-Src inhibitor.  
2.3: The Biphenyl Library 
 The biphenyl moiety was hypothesized to be a promising scaffold as it is found in 4.3% 
of all molecular frameworks of known drugs  and high throughput screening libraries.5-7 Its 
advantageous size and shape allows for high-affinity binding to various pockets on diverse 
protein surfaces.5-7 Additionally, this privileged scaffold provides a means for versatility through 
facile optimization. A library of 300 compounds, organized into three subgroups, containing the 
biphenyl moiety was synthesized. The average molecular weight of the compounds within the 
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library was 365.8. The first group investigated was substituted biphenylethylacetamides. 
Further, acetyl replacements of these substituted biphenylethylacetamides were synthesized 
and evaluated. The third subgroup was comprised of compounds more peptidic in nature; as 
they resembled N-acetyl substituted biphenyl amino acids. (Figure 2.1) This work was 
completed with help from Dr. Sonali Kurup. 
 
Figure 2.1: Common substructures of molecules within the biphenyl library  
 
2.3.1: Top Ring Substitutions and Acetyl Replacements 
 In an effort to efficiently prepare compounds that would sufficiently probe the substrate 
pocket, the unsubstituted biphenylethylacetamide compounds could be easily optimized not 
only at the top ring, but also at the acetyl moiety. Therefore, the subsequent sub-library of 
compounds that was prepared not only contained top ring modifications, but also employed 
various replacements for the acetyl moiety.   
The first group of compounds synthesized was the substituted biphenylethylacetamides 
prepared through Suzuki reactions involving various substituted phenyl boronic acids and 
acetylated 4-bromo(phenylethyl)amine. (Figure 2.2) Focusing primarily on the boronic acids 
available, a diverse set of electron-withdrawing groups as well as electron-donating groups 
were explored. These compounds would hopefully lend to the better understanding of the 
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tolerance and flexibility of the substrate binding pocket. Thus, this subgroup of the biphenyl 
library explored only modifications of the biphenyl top ring.  
 
Figure 2.2: Synthesis scheme for the preparation of the substituted biphenylethylacetamides. 
a.This is the most common route to synthesize the compounds, however, synthetic 
optimizations were utilized when needed. 
 
 
To further explore the size constraints of the substrate-binding pocket, acetyl 
replacements were employed on the substituted biphenylethylacetamides. These replacements 
varied from peptidic, such as amino acids, to substituted benzoyl chlorides and benzoic acids. 
The use of these diverse replacements allows for the better understanding of the substrate-
binding pocket’s flexibility.  
2.3.2: N-acetyl Substituted Biphenyl Amino Acids  
 In order to instill diversity into the biphenyl library, we designed, synthesized and 
evaluated the third sub-group of the biphenyl library, the N-acetyl substituted biphenyl amino 
acids. These compounds investigated amino acid-like inhibitors of c-Src. Structurally, the sub-
group of N-acetyl substituted biphenyl amino acids consists of the biphenyl appended to an 
amino acid that is ‘capped’ by an acetyl group, or an acetyl replacement at the N-terminus. 
Again, retaining a similar strategy to the biphenylethylacetamides, both top ring substitutions 
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and acetyl replacements were investigated to further probe the substrate-binding pocket’s 
flexibility.  
2.4: Evaluation 
 With such a large library, it was critical to devise an appropriate approach that carefully, 
yet efficiently concentrates the large number of compounds into a more manageable subset of 
compounds. Because of this, our lab developed a time-resolved fluorescence resonance energy 
transfer (TR-FRET) binding assay which allowed for the primary evaluation of the library in such 
a manner that those compounds that bind undesirably to the ATP-binding pocket could be 
easily identified and removed from any further screens. Simultaneously, the compounds were 
screened using the TR-FRET method for substrate-competitive binding. Secondarily, once a 
smaller subset of compounds of interest was generated, evaluating the affinity of the 
compounds using a pyrene substrate fluorescence assay proved more practicable.24 The design 
and optimization of the TR-FRET assay was performed by Dr. Steven Bremmer.  
2.4.1: TR-FRET Evaluation 
 In order to elucidate only those compounds with the propensity to bind in the substrate 
pocket of c-Src, the entire library was subjected to analysis by two separate antibody-based TR-
FRET binding assays. (Figure 2.3) In order to better assess the mode of binding of the inhibitors, 
the library was incubated with one of two probes along with His-tag labeled c-Src protein and a 
Europium labeled His-tag antibody. The inhibitor’s ability to out-compete the binding of an ATP-
binding probe as well as a bivalent-binding probe was evaluated. The compounds of interest 
would then not affect the FRET signal measured by fluorescence of the ATP-binding probe, as 
they would not bind in the ATP pocket. However, the compound would not allow a FRET signal 
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to occur, as demonstrated by a decrease in fluorescence, when in the presence of the 
bisubstrate-binding probe. The inhibitor binds to the substrate pocket, thereby preventing the 
probe from binding to form a FRET pair. The inhibitors chosen from this initial screen did not 
compete with the ATP-binding probe, but out-compete the bisubstrate-binding probe greater 
than or equal to 50 percent. Consequently, fourteen compounds were carried through to a 































Figure 2.4: The 14 biphenyl compounds extracted from the TR-FRET primary screen 
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2.4.2: Pyrene Substrate Fluorescence Assay Evaluation 
 These fourteen compounds were then evaluated by a pyrene substrate fluorescence 
assay.24 In this kinetic assay, a pyrene-containing c-Src substrate was incubated with the 
inhibitor and the kinase domain of c-Src while fluorescence was measured. The pyrene side 
chain and tyrosine side chain of the substrate are involved in a π-π stacking interaction which 
results in a quench of the ability of the pyrene to fluoresce. If the tyrosine is phosphorylated by 
the kinase, this interaction is disrupted and fluorescence is detected. A good inhibitor would 
then prevent the phosphorylation event and a decrease of fluorescence would occur. (Figure 
2.5) The IC50 values of the fourteen compounds were obtained against c-Src including the 









Figure 2.5: A schematic of the pyrene substrate fluorescence assay used as a secondary screen 






2.4.2.1: Results  
 Utilizing the pyrene substrate fluorescence assay, the compounds were evaluated for 
efficacy against c-Src kinase domain (KD), the physiologically relevant c-Src three domain (3D), 
and the clinically observed mutation of the ATP-binding pocket, c-Src T338M. When evaluating 
a compound against the kinase domain alone, we hope to screen the compounds for the ability 
to bind to the substrate-binding pocket of the kinase. Whereas, evaluating the compounds 
against the entire protein aims to screen the compound in more physiological-like conditions 
with the hope that the compound can still inhibit the kinase. Furthermore, we also evaluated 
the compounds against the T338M c-Src mutation. This mutation is found in the hinge region 
between the N and C lobes of the PTK. This gatekeeper residue regulates the accessibility of a 
hydrophobic pocket in the back of the ATP-binding pocket of an active kinase. Resistance 
against known ATP-competitive inhibitors and therapeutics can originate with a mutation at 












  c-Src Kinase Domain c-Src Three Domain c-Src T338M 
BiPH  Ave IC50
a Std Dev Ave IC50
a Std Dev Ave IC50
a Std Dev 
47 > 1000 -  298.3 52.3 > 1000  - 
50 560.2 65.9 545.3 627.1 605.6 281.9 
65 60.4 31.2 17.2 10.9 26.4 12.6 
85 260.0 3.3 61.5 75.0 500.5 7.9 
101 191.5 30.6 130.4 101.4 217.9 39.0 
108 1147.3 440.9 NAb NAb > 1000 -  
142 218.4 97.2 NAb NAb NAb NAb 
230 570.6 50.1 636.5 545.3 333.6 23.5 
240 74.1 3.3 40.7 42.6 145.9 19.2 
248 > 1000 -  > 1000  - 77.6 16.3 
250 97.4 20.9 126.8 157.2 54.1 18.8 
259 22.3 4.0 6.9 0.2 28.0 2.7 
264 378.0 14.5 88.4 48.6 197.6 34.6 
280 181.7 10.5 150.0 33.9 329.5 207.0 
a.All reported values in µM 
b.Compound was not evaluated under these conditions 





The structures of the highlighted compounds shown in Table 2.1, are shown below in 
Figure 2.6. BiPH 65 is a substituted biphenylethylacetamide, while BiPH 250 and BiPH 259 are 
examples of the N-acetyl substituted biphenyl amino acid sub-group within the biphenyl library. 
Interestingly, both BiPH 250 and BiPH 259 are structural isomers, as BiPH 250 is the 3-
methylphenyl isomer and BiPH 259 is the 4-methylphenyl isomer. Additionally, both 
compounds BiPH 65 and BiPH 259 have similar ligand efficiencies of about 0.100 kcal/mol/non 
H atoms. However, BiPH 250 has a much lower ligand efficiency of 0.043 kcal/mol/non H 
atoms. Ligand efficiency has been previously used to serve as a means to evaluate and optimize 
Table 2.1: Data from the screens against the fourteen compounds of interest 
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fragment or lead compound hits as it quantifies the ability of a compound to bind with relation 
to the non-hydrogen atoms.28,29  
 
 
Figure 2.6: Compounds of interest from the secondary screen  
 
 
Compounds BiPH 65, BiPH 250, and BiPH 259 not only displayed IC50 values of interest 
for c-Src kinase domain, but they also inhibited the full three domain c-Src as well as the 
gatekeeper mutation. The three compounds of interest have affinities for the c-Src protein 
kinase domain (KD) and the full c-Src protein in the low, double digit micromolar range. Most 
notably, when evaluated against the T338M gatekeeper mutation of the c-Src protein, BiPH 65 
was 2-fold more potent (IC50 26.4 μM). Both BiPH 250 and BiPH 259 also inhibit all three c-Src 
forms in the low double digit micromolar range. However, BiPH 259 inhibits the three-domain 
c-Src with a single digit IC50 of 6.9 μM.  
Controls using high and low ATP concentrations as well as high substrate concentrations 
were carried out with all three compounds against kinase domain c-Src. (Table 2.2) This 
evaluation provided us with a quick means to evaluate whether or not the compounds may be 




  High [ATP]b Low [ATP]c 
High 






65 14.8 18.7 188.0 60.4 
250 80.4 63.7 40.2 97.4 
259 85.4 83.6 336.4 22.3 
 
  a.All reported values in µM 
 b.5 mM ATP, 45 µM pyrene substrate 
 c.100 µM ATP, 45 µM pyrene substrate 
 d.500 µM pyrene peptide, 1 mM ATP 





2.4.2.2: Lineweaver-Burk Analysis of compounds  
As previously demonstrated, both compound BiPH 65 and BiPH 259 show some 
competition with substrate concentrations. This was illustrated by the increased IC50 values 
when the concentration of substrate was increased. BiPH 250 seems to lack substrate-
competitive binding to c-Src, and it is hypothesized that this compound may bind in an 
allosteric manner to c-Src. In order to further illustrate the modes of binding for the 
compounds, Lineweaver-Burk analysis of BiPH 65 and BiPH 259 was used. Such plots allow for 
further refinement of the binding mode as they suggest that compound  BiPH 259 binds in a 
mixed mode, being both ATP-competitive as well as substrate-competitive. (Figures 2.7, 2.8) 
The data for these plots unfortunately do not follow a clear trend. This makes the 
characterization of the binding mode of compound BiPH 259 difficult. However, the analysis of 
BiPH 65, shown below, strongly suggests the compound binds in the desired ATP-
noncompetitive, substrate-competitive binding mode. (Figures 2.9, 2.10) Additionally, as shown 




in the KM plots for this analysis provided in Appendix A, we notice that the KM values remain 
constant, while the Vmax values decrease slightly with respect to ATP. This trend is characteristic 
of non-competitive inhibition. With respect to the substrate plot, we notice that the KM values 












































































Figure 2.10: Lineweaver-Burk Plot of compound BiPH 65 vs. pyrene substrate 
 
Additional plots that explore the binding modes of compounds BiPH 65 and BiPH 259 are 
included in Appendix D. Please refer to this appendix for the Hanes analysis of these two 
compounds. We believe that the Hanes analysis for BiPH 65 vs. ATP may further support the 
ATP-noncompetitive binding mode. However, the Hanes analysis for BiPH 259 is less clear and 
consequently inconclusive.  
 The binding mode of BiPH 65 was further characterized through the use of the TR-FRET 
assay. Full dose response curves were run with each probe, ATP-competitive and bisubstrate-
competitive. Using the same principles as described with the primary screen, we predicted that 
BiPH 65 would not out-compete the ATP-competitive probe and therefore, we would generate 
a FRET signal at any concentration of the inhibitor. Supporting this idea, the average EC50 of the 
compound when evaluated against the ATP-competitive probe is greater than 1000 μM. 






















competitive probe and an EC50 curve would be generated. The average EC50 of the compound 
when evaluated against the bisubstrate-probe is 112.8 ± 41.9 μM. 
2.4.2.3: Analogs of BiPH 65  
In hopes to gain potency, analogs of BiPH 65 were synthesized focusing on replacing the 
acetyl group. Benzyl, phenyl, phenyl urea, phenyl sulfonamide, and acetyl glycine replacements 
were employed. Regrettably, no analog displayed better potency for c-Src kinase domain than 




Figure 2.11: Analogs of BiPH 65 prepared 
 
 
Compound c-Src KD 
   Ave IC50
a 
BiPH 65 60.4 
BiPH 65-A > 1000 
BiPH 65-B > 1000 
BiPH 65-C > 1000 
BiPH 65-D > 1000 
BiPH 65-E 168.8 
 
a.All reported values in µM 
Conditions: 1 mM ATP, 45 µM pyrene substrate, 30 nM enzyme 
 
 
Table 2.3: IC50 values of BiPH 65 analogs prepared 
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2.4.2.4: Molecular Dynamics Simulations  
Molecular modeling simulations were performed on BiPH 65 by Dr. Kelly L. Damm-
Ganamet. These simulations further suggest an ATP-noncompetitive mode of binding as the 
compound appears to favor binding in a pocket formed by the activation loop of c-Src. 
Additionally, through binding at the activation loop, we hypothesized that the compound may 

























Figure 2.12: Molecular modeling of BiPH 65 and c-Src. Shown in magenta, BiPH 65 prefers 
binding in an ATP-noncompetitive mode as it appears to prefer binding to the inactive 





To experimentally investigate this, BiPH 65 was evaluated against the constitutively active, pY-
416 c-Src. Assay data gleaned from this evaluation support the inability of the compound to 
bind the active conformation of c-Src (IC50 >1000 μM). The T338M c-Src data also support such 
a binding mode, as it is suggested that the gatekeeper mutation favors the inactive 
conformation of the protein and shown previously, BiPH 65 is two-fold more potent for the 
gatekeeper than the kinase domain of c-Src.26 
2.4.2.5: Selectivity of BiPH 65 
In the rational design of kinase inhibitors, as mentioned above, an important property of 
the inhibitor is its ability to be selective for the kinase of interest as off-target kinase binding 
correlates with heightened toxicity effects. To investigate the selectivity of BiPH 65 we 
evaluated its potency against two PTKs sharing significant sequence similarity with c-Src. The 
first, Hck, is a Src-family PTK that shares 72% sequence similarity, 59% sequence identity with c-
Src.30 The second, c-Abl, is not a member of the Src-family but shares 49% sequence identity 
and 68% sequence similarity with c-Src. The thought is that in utilizing such highly homologous 
proteins, if the compound was not selective for c-Src, it would bind with similar potency to 
these other PTKs. After evaluation with both of these PTKs it was discovered that BiPH 65 did 
not inhibit either PTK (Hck IC50 > 500 μM, c-Abl IC50 > 500 μM) and therefore has selectivity for 
c-Src over c-Abl and c-Hck.  
2.4.2.6: Cellular proliferation studies  
Cellular proliferation studies were performed with BiPH 65 using the HT-29, human 
colon carcinoma, cell line. Following a 72 hour exposure to the selective inhibitor, the 50% 
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growth inhibition value was 10.3 μM. (Figure 2.13) Therefore, BiPH 65 is a compound capable 
of entering the cell and inhibiting cell growth. 
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Figure 2.13: GI50 curve of BiPH 65 and HT-29 cells 
 
2.5: Conclusion 
 The design of substrate-competitive inhibitors of PTKs is a challenging task. 
Furthermore, the design of a selective substrate-competitive inhibitor is daunting as there is 
little to no structural data available for the substrate binding pocket of these kinases. 
Therefore, the rational design of such compounds can be executed by means of exploiting the 
use of privileged scaffolds often found in high throughput screening libraries, as they are known 
to be promiscuous binding fragments. We demonstrated that through the use of the privileged 
biphenyl scaffold we were able to design a compound that does not compete with ATP in 
binding to c-Src. Additionally, this compound is cell permeable and selective with regards to 
other highly homologous PTKs. BiPH 65 is a c-Src selective, substrate-competitive inhibitor that 
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may prove to be a useful tool in probing the biological activity of the kinase as it favors binding 
to the inactive conformation of c-Src. We further outline the importance of the use of our 
newly developed, specialized TR-FRET screen. With this screen, we were able to easily and 
efficiently evaluate a large number of compounds for not only ATP-competitiveness, but also 
for substrate-competitiveness.  
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The Investigation of 4-fluorotyrosine as a Suitable Scaffold to Prepare Substrate-Competitive 
c-Src Inhibitors 
3.1: Abstract 
 The class of enzymes known as protein tyrosine kinases (PTKs) has been associated with 
disease states such as cancer, inflammation and diabetes when kinase activity is dysregulated. 
The non-receptor protein tyrosine kinase c-Src regulates diverse cellular processes that include 
cell survival, angiogenesis, motility, migration and invasion as well as cell proliferation. 
Discovered and classified in the 1970s, the c-Src proto-oncogene is characteristically 
overexpressed in various cancers such as breast, colon, pancreatic and ovarian.1-3 Although 
regarded as the first PTK characterized, there is limited structural data that exists for c-Src 
pertaining to the substrate binding pocket.2,4-8 This fact holds true for many PTKs. The end 
result is that the rational design of inhibitors is hindered, as not much is known about the often 
shallow and solvent exposed substrate-binding pocket. The main motivation behind our work 
rests in better understanding this PTK and, more specifically, garnering knowledge about the 
substrate-binding site of the kinase. We aim to develop peptidomimetic compounds that act 
not only as inhibitors of the kinase activity, but which also probe the substrate pocket to 
provide more structural information.  
 Previously published literature outlined the use of peptides containing fluorinated 
tyrosyl residues as substrate-competitive inhibitors of the insulin receptor kinase, a fellow PTK 
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family member.9,10 Due to this documented success, an effort in our laboratory was made to 
further investigate this fluorinated tyrosyl residue with respect to the development of inhibitors 
of c-Src. Through stepwise modifications of the inhibitor peptide Ac-EEEI(4F)YGEFEA-NH2, a 
library of (4F)tyrosine containing peptidomimetics were synthesized and evaluated as inhibitors 
for c-Src. A full range of SAR optimizations on the parent compound were synthesized and 
evaluated. Although initially very promising, these fluorinated peptidomimetics undesirably 
bound to c-Src in an ATP-competitive, substrate-noncompetitive mode.    
3.2: Introduction 
 Protein tyrosine kinases (PTKs) are a family of 90 enzymes that catalyze the transfer of 
adenosine triphosphate’s (ATP) γ-phosphate to the hydroxyl moiety of a tyrosine of the natural 
peptide substrate and thusly, initiate signaling cascades that are critical for cell functions 
including cell growth, cell division, and apoptosis.11,12 Disease states arise when cellular events 
such as these are dysregulated by aberrant kinase activity. Examples of disease states 
correlated with this activity include cancer, rheumatoid arthritis, cardiovascular disease and 
neurodegenerative disease.13 Because of this, PTKs provide an attractive therapeutic target and 
the 518 member protein kinase family consumes thirty percent of pharmaceutical research 
efforts toward the discovery of inhibitors to target and regulate such activity.14-18 
 In 1976, c-Src was determined to be the first proto-oncogene and only four years later 
the enzyme was classified as the first PTK.2 Cell survival, angiogenesis, motility, migration and 
invasion, and cell proliferation are regulated by c-Src.1,2 Furthermore, the over-expression of c-
Src has been linked to cancers such as breast, colon, pancreatic, and ovarian.1,2 Twenty percent 
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of HER2-positive breast cancers have been linked with c-Src over-expression, and thus, the 
excessive downstream activation of the PTK has been thought to be in part, the cause of HER2-
positive breast cancer resistance to the drug, Herceptin.19,20 The inhibition of c-Src would 
explore a new means by which to combat this clinically relevant resistance.  
 Current approved therapeutics aimed at regulating PTK activity are all ATP-competitive 
in nature. This class of inhibitors binds within the ATP pocket of the PTK and competes with 
cellular levels of ATP. Although extremely potent, these compounds often suffer from issues of 
selectivity being that the ATP pocket of each of the individual 518 protein kinases is highly 
conserved. As such, ATP-competitive inhibitors bind promiscuously, and this off-target binding 
can lead to issues with undesired toxicity.17,21-23 Secondarily, these inhibitors must compete 
with concentrations of ATP as high as 10 mM within a cancer cell although kinases typically 
have an affinity for ATP only in the low micromolar range.14,17,24 The excess of cellular ATP 
assures the saturation of the ATP pocket and thus, requires high affinity inhibitors in the low 
nanomolar to picomolar range in order to achieve in vivo activity. Lastly, common mutations of 
the ATP-binding pocket often lead to rapid drug resistance and loss of efficacy. Such clinically 
relevant mutations include the T338M mutation of c-Src.  
 Determined to design selective inhibitors of c-Src, we focused on the investigation of 
substrate-competitive inhibitors. Unlike the ATP-binding pocket, the substrate-binding pocket is 
less conserved among PTKs. Unfortunately, there is little known structural knowledge existing 
about the substrate-binding pocket.2,4-8 The shallow pocket is thought to be solvent exposed 
and most likely becomes more defined upon the binding of a substrate. By targeting the 
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substrate pocket, we strive to improve the selectivity of our inhibitors. Additionally, most 
natural substrates are found present in cells at or below their KM values allowing for 
compounds that do not necessarily need low nanomolar potencies, but which may have low 
micromolar affinity for the kinase.22,24,25 Notably, the common mutations that are found with 
ATP-competitive inhibitors could potentially be avoided as the inhibitor targets another pocket 
within the catalytic domain. 
In order to explore the substrate-binding pocket, we began with peptidic substrates that 
bind to c-Src favorably. Upon elucidating such peptides, we aimed to replace the 
phosphorylatable hydroxyl moiety of tyrosine of the substrate with a non-phosphorylatable 
pharmocaphore which would, by design, inhibit the kinase activity. From there, truncation 
through a stepwise fashion would allow for the evaluation of small peptidomimetic inhibitor 
compounds. With this in mind, previous reports on the development of peptidic inhibitors for 
the PTK, insulin receptor kinase, utilized a (4F)tyrosyl residue and provided a foundation for this 
project.9,10 Compared to tyrosine, the (4F)tyrosine and its derivatives have altered ionic and 
nucleophilic character of the phenolic moiety.9 Further, a fluorine atom is only slightly larger 
than a hydrogen atom and therefore, significant steric interference should not be observed. 
Due to this, the inhibitor would mimic the natural substrate, but would not allow for 
phosphorylation.9 Using the insulin receptor kinase (4F)tyrosine inhibitor model, we set out to 
develop peptidomimetic inhibitors of c-Src that would desirably bind at the substrate pocket. 
Peptidomimetic compounds are thought to be able to bind similarly to the kinase target as the 
larger peptide in addition to providing a higher proteolytic stability and a higher bioavailability 
than the natural peptide.26  
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3.3: Initial studies 
 Determined to develop a substrate-competitive inhibitor, our foundation for compound 
design rested with a known c-Src substrate sequence. The binding affinity (KM) for the c-Src 
optimal substrate peptide sequence, Ac-EEEIYGEFEA-NH2, is 34 ± 8 µM. Replacing the tyrosine 
in this sequence with a (4F)tyrosine residue, the resulting peptide (Ac-EEEI(4F)YGEFEA-NH2) was 
synthesized via standard Fmoc solid phase peptide synthesis (SPPS) methods on Rink amide 
resin using microwave-assisted peptide coupling. (Figure 3.1) 
 
 
Figure 3.1: (Top) The structure of the c-Src optimal peptide, Ac-EEEIYGEFEA-NH2. (Bottom) 





This potential inhibitor peptide sequence was first evaluated using a nucleoside diphosphate 
kinase assay (NDPK).27 (Figure 3.2) This coupled fluorescence-based assay incorporates the use 
of a phosphorylated nucleoside diphosphate kinase bound to a fluorescent cumerin (NDPK~P). 
As the kinase uses ATP to phosphorylate the substrate, ADP is produced. This ADP binds to 
NDPK~P, the phosphate is transferred to ADP, producing ATP and a measureable decrease in 
fluorescence is observed and quantified as enzyme activity.27 The data gleaned from this study 
suggest that the tetrafluorotyrosine containing peptide does not become phosphorylated by c-
Src as no fluorescence is observed correlating to a lack of enzyme activity. (Figure 3.3)  
Figure 3.2: A schematic of the nucleoside diphosphate kinase assay (NDPK) 
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 Since the data suggest that the tetrafluorotyrosine containing peptide does not become 
phosphorylated, the peptide was evaluated as an inhibitor using the pyrene substrate 
fluorescence assay.28 This assessment demonstrated that Ac-EEEI(4F)YGEFEA-NH2 inhibits c-Src 
with an IC50 of 116.5 ± 63.2 µM. (Figure 3.4) With these encouraging results in our hands, we 
aimed to begin work in the design of small tetrafluorotyrosine containing peptidomimetic 
compounds. These initial studies were performed by Meghan E. Breen in our laboratory.  
 
 
Figure 3.3: NDPK assay results evaluating Ac-EEEI(4F)YGEFEA-NH2 against c-Src, illustrates a 































3.4: Library Generation 
 Focusing on our initial studies, we began with the truncation of the peptide to a single 
residue, Fmoc-4F-Tyrosine-OH. This amino acid was synthesized via reported synthetic methods 
shown in Figure 3.5.29 The allyl group was removed as the last step of the synthesis of the 
compound. The preliminary library would focus on the optimizations of the C-terminus, while 
retaining the Fmoc N-terminus protecting group. The second library would explore Fmoc 
replacements of the tetrafluorotyrosine residue. Our evaluations show that these compounds 
would prove to be not very potent. Thus, in the final group of compounds prepared, we utilized 
solid phase peptide synthesis techniques to quickly investigate optimizations on the best Fmoc 
replacement, the phenyl urea, on a carboxylamide amino acid scaffold.  
Figure 3.4: Pyrene substrate assay results evaluating Ac-EEEI(4F)YGEFEA-NH2 against c-Src. IC50 





3.4.1: C-terminus Optimization 
 The C-terminus optimization series numbered 3 compounds in total. We aimed to 
append an easily modified moiety to the parent carboxylamide compound. Thus, we evaluated 
the parent compound (IV-sms-93), a phenyl substitution (IV-sms-80), and lastly a benzyl 
substitution (IV-sms-89). (Figure 3.6)  
 
Figure 3.5: Preparation of the allyl protected Fmoc-(4F)Tyrosine-OH amino acid  
Figure 3.6: The C-terminus library of the (4F)Tyrosine compounds 
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 The carboxylamide analog provided the least potent evaluation of this small library. As it 
stood, this compound (IV-sms-93) did not inhibit c-Src very well. However, both the phenyl and 
benzyl analogs proved to be of slightly more interest. Of these two analogs, the most potent 
analog was the benzyl C-terminal replacement, IV-sms-89. With an IC50 of 131 μM, it was 
hypothesized that further optimizations of both the benzyl group and the replacement of the 
Fmoc protecting group could provide a fully optimized and potent inhibitor of c-Src. Prior to 
performing a SAR study on the benzyl moiety, the next set of optimizations to be performed 
would be on the N-terminus of the compound, exploring replacements of the large Fmoc 
protecting group while preserving the newly discerned benzyl C-terminus optimization.   
3.4.2: N-terminus Optimization 
 Retaining the C-terminus benzyl, a series of eight compounds was synthesized. These 
compounds would explore various replacements for the Fmoc protecting group. These analogs 





In addition to a benzyl (3), phenyl (4), phenyl sulfonamide (1) and phenyl urea (6) replacements, 
we evaluated the potency of compounds that contained more peptidic substitutions by 
incorporating amino acid residues such as acetylated isoleucine (8) and CBZ protected 
isoleucine (7), as well as evaluating an isovaleryl replacement (2) and a BOC group replacement 
(5) of the Fmoc group.    
 Of these eight compounds, none displayed potency significantly greater than that of the 
Fmoc-containing parent compound (IC50: 131 μM). These values are compiled in Table 3.1.  
 
 







 Table 3.1: Evaluation of N-terminus optimization library 
 
Disappointingly, the analogs did not provide the increase in potency we had hypothesized. 
However, it should be noted that analog (6), the phenyl urea containing compound, did have 
similar potency to the parent compound as it inhibited c-Src with an IC50 of 129 ± 25 µM.  
3.4.3: Carboxylamide Compounds 
Although we could not find a suitable optimization within the N-terminus library, we 
wished to delve further into investigating the phenyl urea modification. In order to increase the 
ease of preparing this library, we focused only on modifying the N-terminal. We achieved this 
by appending the Fmoc-(4F)tyrosine-OH to Rink amide resin via standard Fmoc solid phase 
peptide synthesis methods. Once coupled and Fmoc deprotected, the resin was dried and split. 
Utilizing a diverse library of substituted phenyl isocyanates, we prepared a SAR library of 
sixteen carboxylamide compounds. (Figure 3.8) Each compound was cleaved from the resin, 
purified and evaluated using the pyrene substrate fluorescence assay.28 The parent compound 
of this library is denoted by H in Table 3.2. 
R Ave IC50 (µM) 
1 796 ± 184 
2 318 ± 67 
3 > 1000 
4 346 ± 53 
5 > 1000 
6 129 ± 25 
7 > 1000 













Table 3.2: Carboxylamide analog library evaluation 
 
Out of this library, we discovered one compound of particular interest. The (3F)phenyl urea 
analog was evaluated to have an IC50  of 12 ± 4 μM for c-Src. This was rather encouraging as 
R Ave IC50 (µM) 
H  119 ± 33 
2Cl 683 ± 96 
3Cl 800 ± 133 
4Cl 605 ± 123 
2CF3 1098 ± 138 
3CF3 687  ± 4 
4CF3 > 500 
2F 414 ± 94 
3F 12 ± 4 
4F 681  ± 118 
2OMe > 500 
3OMe 268 ± 69 
4OMe > 500 
2Me 28 ± 4 
3Me 159 ± 49 
4Me 307 ± 59 
Figure 3.8: The carboxylamide library of the (4F)Tyrosine compounds 
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most analogs previously evaluated did not have potencies in the low double digit micromolar 
range. Additionally, because this compound is peptidic in nature, being an amino acid analog, 
we anticipated that it would bind in the substrate pocket in an ATP-noncompetitive, substrate-
competitive desired binding mode with c-Src.  
 Further evaluation of the (3F)phenyl urea analog included a selectivity study. While our 
current assay protocol screens the compounds against the kinase domain of c-Src, we wanted 
to assess the ability of the compound to inhibit the physiological relevant c-Src protein. To do 
this, we tested the compound against the full three domain protein (c-Src WT 3D). Additionally, 
we wished to gather data pertaining to the compound’s ability to inhibit a clinically relevant 
mutation of c-Src (c-Src T338M). Lastly, we would evaluate the (3F)phenyl urea analog against 
two PTKs that share high sequence similarity with c-Src, these PTKs are c-Abl and c-Hck. The 




Conditions: 1 mM ATP, 45 µM pyrene substrate, 30 nM enzyme 
Table 3.3: Lead compound evaluation 
 
Kinase  Ave IC50 (µM) 
c-Src WT KD 12 ± 4 µM 
c-Src T338M > 500 µM 
c-Src WT 3D 12 ± 0.4 µM 
c-Abl 46 ± 18 µM 
c-Hck 23 ± 2 µM 
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The (3F)phenyl urea analog inhibits the full three domain protein with a similar potency as it 
inhibits the kinase domain alone. However, the analog unfortunately does not inhibit the 
T338M gatekeeper mutant. Nevertheless, the (3F)phenyl urea analog does show some 
selectivity for c-Src over the other PTKs evaluated (4-fold over c-Abl, 2-fold over c-Hck).  
 In order to investigate the binding mode of the (3F)phenyl urea analog, we ran control 
experiments that would evaluate the compound at high and low concentrations of ATP and 
high concentrations of substrate. From these experiments, we were disappointed to find that 
the data suggest the analog may compete with ATP. As shown in Table 3.4, at high 
concentrations of ATP, the IC50 increases, while at low concentrations of ATP, the IC50 
decreases. Interestingly, the IC50 of the compound decreased at high substrate concentrations. 
This data suggests that the compound is not substrate-competitive. In order to make a more 






Table 3.4: Control experiment data 
 
Control Experiment Ave IC50 (µM) 
High ATP (5 mM ATP, 45 μM pyrene substrate) 16 ± 2 µM 
Low ATP (100 μM ATP, 45 μM pyrene substrate) 5 ± 2 µM 
High Pyrene Substrate (1 mM ATP, 500 μM pyrene substrate) 5 ± 3 µM 




Much to our disappointment, Lineweaver-Burk analysis suggests that with respect to ATP, the 
compound shows a trend characteristic of mixed inhibition. These results appear to be 
inconclusive. The substrate analysis suggests a competitive binding mode. The plots are 























Figure 3.9: Lineweaver-Burk analysis of the (3F)phenyl urea analog against varying 






This mode of binding is further illustrated with KM plots for these analyses, provided in 
Appendix B. As a means to better characterize the binding mode of the compound, we also 
analyzed the data using a Hanes plot. This data is provided in Appendix D. Much to our 
disappointment, this method of analysis provides us with more inconclusive results. With 
respect to compound V-sms-174 3F, we cannot yet conclusively characterize the binding mode. 
3.5: Conclusions 
 Although initially promising, it can be deduced from this project that small 
peptidomimetic inhibitor compounds may not bind in the same manner as their larger peptide 


















Figure 3.10: Lineweaver-Burk analysis of the (3F)phenyl urea analog against varying 
concentrations of pyrene substrate. 
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range of SAR optimizations of the parent compound, we arrived at a compound that had very 
promising IC50 values for a substrate-competitive inhibitor. Unfortunately, after control 
experiments and Lineweaver-Burk analysis, we were saddened to learn that we cannot easily 
interpret the binding mode of the compound.  
 Despite our unfortunate discoveries with regards to the design of a substrate-
competitive tetrafluorinated tyrosine containing inhibitor, peptidomimetic inhibitors still serve 
as a general basis for the development of future substrate-competitive inhibitors. By taking a 
known substrate peptide and replacing the phosphorylatable residue with a non-
phosphorylatable pharmacophore, an inhibitor peptide can be elucidated. Through the 
truncation of this then known inhibitor peptide, there is a great potential to arrive at small 
peptidomimetic compounds that have the likelihood of binding in the substrate pocket to 
potently inhibit the kinase target.  
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The Identification of Small Molecule, Allosterically-binding c-Src Kinase Inhibitors through the 
use of a Screening Library. 
4.1: Abstract 
The non-receptor protein tyrosine kinase c-Src is known to regulate many diverse 
cellular processes including cell survival, angiogenesis, motility, migration and invasion, as well 
as cell proliferation. Discovered in the 1970s, the proto-oncogene is known to be over-
expressed in breast, colon, pancreatic and ovarian cancers.1-3 Our motivations behind this work 
were to elucidate new molecular scaffolds on which to develop substrate-competitive small 
molecule inhibitors of c-Src.  
Using a 1000 compound-containing library obtained from Maybridge Chemical, we 
evaluated the compounds against the clinically relevant T338M c-Src ‘gatekeeper’ mutant 
kinase. This screen was performed using high ATP concentrations in hope of eliminating any 
fragments that may preferentially bind to the ATP binding pocket of the kinase, as we desire to 
elucidate structures that would favorably bind to the substrate binding pocket of the kinase. 
The data from this exploratory screen gleaned nine compounds that displayed favorable 
inhibitory activity in the biochemical assay for c-Src. The compounds of interest inhibited 
T338M c-Src at a value greater than or equal to 50 percent inhibition. This inhibition value was 
chosen as it was greater than three standard deviations from the mean percent inhibition value 
of the entire 1000 compound library evaluated. Of these nine compounds, three compounds 
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were further studied due to the predicted ease of modification and optimization of the 
fragment. Preliminary controls testing for an ATP-noncompetitive mode of binding found only 
one fragment: [1]. (Figure 4.1) This compound, 5-chlorobenzo[b]thiophene-3-carboxylic acid, 
inhibited the T338M c-Src ‘gatekeeper’ mutant with an IC50 of 7.9 μM and the wild type c-Src 
protein with an IC50 of 9.4 µM. Additionally, this compound exhibits selectivity for c-Src over 
other closely related PTKs (c-Abl, c-Hck). Lineweaver-Burk data supports an ATP-
noncompetitive binding mode. However, substrate Lineweaver-Burk plots are more 





Protein tyrosine kinases (PTKs) are a class of proteins totaling 90 different enzymes that 
functionally facilitate the transfer of the γ-phosphate of a molecule of adenosine triphosphate 
(ATP) to a substrate’s phenolic tyrosine residue. This transfer initiates signaling cascades critical 
for important cell processes such as cell growth, cell division, and programmed cell death.4,5 
The interruption of these cellular events has been found to be influential in various disease 
states including cancer, rheumatoid arthritis, cardiovascular disease, as well as 




neurodegenerative disease.6 Due to their critical role in such processes, PTKs have been 
intensely studied and targeted. Pharmaceutical research devotes thirty percent of its efforts to 
the elucidation of therapeutics that target this superfamily of enzymes.7-11 
Discovered in 1976, c-Src was deemed to be the first proto-oncogene and later in 1980, 
was further classified as a PTK.1 c-Src is known to regulate various cellular processes such as 
survival, angiogenesis, motility, migration and invasion, as well as cell proliferation. c-Src has 
been found to be over-expressed in specific cancers including: breast, colon, pancreatic, and 
ovarian.1,2 Attributable to its over-expression in twenty percent of HER2-positive breast 
cancers, c-Src’s activity is thought to be a cause of Herceptin-resistant HER2-positive breast 
cancer.12,13 As such, the inhibition of c-Src has been explored as a therapeutic means to combat 
this resistance. 
 The understanding of enzymatic activity is fundamental to the rational design of 
effective therapeutics in the current struggle to combat cancer. Therefore, the design of 
selective, small molecule inhibitors is imperative as these molecules can reveal information 
about the enzyme as they lend to the targeting of a specific protein without broadly affecting 
other closely related proteins. This selective probe can study the specific kinase in question, 
leading to a more precise investigation of the kinase activity. Selectivity of these small molecule 
probes is important, as off-target binding of inhibitors can lead to certain toxicity.14 
To date, all FDA approved PTK inhibitors are ATP-competitive as they bind in the highly 
conserved ATP pocket of kinases. These inhibitors are highly potent and therefore are able to 
out compete the high concentrations of cellular ATP often found in cancer cells.9 Although 
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these inhibitors bind with high affinity, they are often impaired by their lack of selectivity.15 As a 
result, ATP-competitive inhibitors are promiscuous due to their ability to bind to many kinases 
downstream from the kinase of interest. These off-target effects are a significant reason for 
toxicity of such inhibitors.10,14-17 
 Our interest rests in the development of substrate-competitive inhibitors for c-Src. Such 
inhibition only involves the competition between a small molecule binding to the substrate-
binding pocket of the kinase and the natural protein substrate.10,17 As a general rule of thumb, 
the substrate-binding pocket is less conserved throughout the 518 member PK families than the 
ATP-binding pockets since kinases bind a number of protein substrates with unique 
sequences.4,18 These protein-protein binding sites are often shallow and solvent exposed, 
producing difficult conditions with which to rationally design small, substrate-competitive 
molecules.8 The lack of structural understanding of various PTKs and their substrate binding 
sites renders the rational design of substrate-competitive inhibitors much more difficult 
without the aid of a crystal structure to model possible inhibitory scaffolds. In order to begin 
work on developing a new set of substrate-competitive small molecule probes for c-Src, we 
chose to evaluate a fragment library sold by Maybridge Chemicals using a biased screen. Our 
motivations in performing this screen were to ultimately obtain a compound that has desirable 
inhibitory activity for c-Src which can be easily optimized to increase the potency of the 
inhibitor. The resulting compound, 5-chlorobenzo[b]thiophene-3-carboxylic acid, [1], displayed 
interesting properties, as it was ATP-noncompetitive and data from Lineweaver-Burk analysis 
appeared to support the hypothesis that [1] binds allosterically to c-Src with an IC50 value of 9.4 
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± 2.8 µM (1 mM ATP, 45 μM substrate). Furthermore, from controls performed with highly 
similar PTKs, [1] displays promising selectivity for c-Src.  
 A true allosteric protein kinase inhibitor, or type IV inhibitor, binds to regions of the 
kinase not associated with the active site of the protein. These inhibitors regulate kinase 
activity through unique mechanisms particular to the specific kinase as they bind to regions 
distant from the ATP-binding pocket.19,20 While the propensity for these compounds to have 
higher selectivity is unknown, these binding sites often tend to be more structurally 
distinct.7,8,20 With regards to both substrate-competitive and allosteric inhibitors, there are 
promising advantages; however, their development is faced with many troubles. Lack of 
structural understanding as well as low micromolar affinities for the PTK are some of the 
obstacles that the design of such inhibitors faces. Here we desire to discuss our findings with 
[1]. 
4.3: Initial studies - The Maybridge Library  
 The Maybridge Chemical Fragment Library is comprised of 1000 compounds with noted 
diversity of structure. This library satisfies the Rule of Three (Ro3) as all of the compounds have 
molecular weights less than or equal to 300, 3 or less hydrogen bond acceptors, 3 or less 
hydrogen bond donors, 3 or less rotatable bonds and a cLogP of 3 or less.21 Through the use of 
high ATP concentrations, we anticipated hits obtained from this library would provide us with a 
molecular framework upon which to develop new substrate-competitive inhibitors as we hoped 
to eliminate ATP-competitive inhibitors from those fragments that are substrate-competitive in 
the library.  
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4.3.1: Preliminary Evaluation  
 The preliminary evaluation of the entire 1000 compound library was performed in our 
laboratory by Michael E. Steffey. Using the pyrene substrate fluorescence assay reported by 
Lawrence and coworkers,22  the 1000 compounds were evaluated for inhibitory potency against 
the T338M c-Src kinase. This was performed by collecting single point percent inhibitory data 
for each compound at 50 µM. The motivations for using this particular c-Src gatekeeper 
mutation rest in clinically relevant mutations that lead to resistance of many tyrosine kinase 
inhibitors. Because of its position in the hinge region between the N and C lobes of the PTK, the 
gatekeeper mutation regulates the accessibility of a pocket in the hydrophobic back cavity of 
the ATP-binding pocket of an active kinase. Subsequently, a mutation of this residue from a 
threonine to a larger, more hydrophobic residue will change the size of this particular back 
pocket and therefore, can lead to resistance of known ATP-competitive inhibitors.23-25 We 
wished to develop a substrate competitive inhibitor that not only inhibits the wild type c-Src 
kinase, but also those mutations that have been shown to be clinically relevant in the discovery 
of inhibitors and therapeutics. Additionally, the compounds were screened at high 
concentrations of ATP [5 mM] with hopes that this level of ATP would prevent the binding of 
those fragments with the susceptibility of binding in an ATP-competitive mode. Figure 4.2 
shows a histogram displaying the percent inhibition results from the initial screen of the 
Maybridge Library screen.  
 From these 1000 compounds, the nine compounds shown in Figure 4.3 emerged with 
favorable percent inhibition values. These nine compounds represent 0.9% of the entire library. 
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The mean percent inhibition value was 1.25% and the standard deviation was 21.1% inhibition. 
We were interested in compounds that showed percent inhibition values that were three times 
the standard deviation (64.6%). However, in order to ensure that we evaluated every possible 
lead, we broadened our search and considered those compounds that had a percent inhibition 
of 50% or greater. Based off of their structures and high percent inhibition values, compounds 
[1], [2] and [3] were chosen to be carried forward for additional screening. Although [4] was 
reported to have 75.9% inhibition, we concluded that there was minimal opportunity to further 
optimize the scaffold and therefore, we chose to forgo its further evaluation. Compounds [1], 
[2] and [3] were hypothesized to provide interesting new scaffolds to begin design of new 
substrate-competitive inhibitors of c-Src. IC50 values of these compounds were obtained at both 
5 mM and 1 mM ATP concentrations, 25 μM substrate concentration for the T338M c-Src 
kinase. This control would allow for in the further evaluation of the compounds to be binding in 
an ATP-competitive mode. Shown below in Figures 4.4 and 4.5 are the IC50 curves of these 
compounds at both concentrations of ATP. 
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Figure 4.2: Histogram of the results from the Maybridge fragment library screen against 
T338M c-Src kinase. The compounds were assayed at 50 μM (n=1) against 30 nM kinase in 
the presence of 5 mM ATP and 25 µM pyrene substrate. Fluorescence was measured in 
kinetic mode and mean velocity of the reaction was calculated over the linear rate from 0.5 - 





Figure 4.3: The nine compounds that were pulled from the initial screen of the Maybridge 
compounds and their percent inhibition values for T338M c-Src. Compounds [1], [2], and 
[3] were further evaluated in a secondary screen in which full IC50 curves were obtained for 
the compounds at varying concentrations of ATP. 
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Figure 4.4: The IC50 curves of compounds [1], [2] and [3] at high concentration of 
ATP [5 mM] and 25 μM substrate. 
Figure 4.5: The IC50 curves of compounds [1], [2] and [3] at a normal concentration 
of ATP [1 mM] and 25 μM substrate. 
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4.3.2: 5-Chlorobenzo[b]thiophene-3-carboxylic acid as a lead compound 
The evaluation of compounds [1] and [2] implies that at varying ATP concentrations, the 
IC50 values of these compounds do not change significantly. This is a characteristic trend of non-
competitive inhibition. However, the data for [3] appears to suggest that it is ATP-competitive, 
as the IC50 value increases significantly in the presence of high concentrations of ATP. Due to 
this, [3] was no longer of interest for further evaluation. With this, our focus shifted to the 
further evaluation of compound [1] as it is more potent than compound [2]. From this data, 
compound [1] was subjected to evaluation of IC50 values for the T338M c-Src kinase at varying 
substrate concentrations. (Figure 4.6) 































 Figure 4.6: The IC50 curves of compound [1] against the T338M c-Src kinase with varying 
concentrations of substrate. 
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As seen above, when the concentration of the pyrene substrate is varied, the IC50 values 
of [1] do not change significantly. Unfortunately, this trend is characteristic of a non-
competitive relationship between the inhibitor and substrate. Knowing this, further evaluation 
of the compound was performed with hopes to fully characterize the lead compound. 
Compound [1] was evaluated against c-Src wild type kinase domain (IC50 9.4 µM, 1 mM ATP, 45 
μM substrate) to confirm that the inhibitor not only could bind to the mutation but also the 
wild type protein. Since [1] inhibits both wild type c-Src as well as the gatekeeper mutant with 
low micromolar potency, the subsequent evaluation to perform would focus on the selectivity 
of the compound. In order to do this, we evaluated its potency against two PTKs that share 
significant sequence similarity with c-Src. As a Src-family PTK, c-Hck shares 72% sequence 
similarity and 59% sequence identity with c-Src.26 c-Abl, while not a member of the Src-family, 
shares 49% sequence identity and 68% sequence similarity with c-Src. In utilizing such highly 
homologous proteins, we assume that if the compound was not selective for c-Src alone, it 
would also bind to these other PTKs with similar affinities. When evaluated against these PTKs, 
compound [1] failed to inhibit either kinase well as c-Src: c-Abl (IC50: 195.0 µM) and c-Hck (IC50 > 

















































Figure 4.7: The Lineweaver-Burk analysis of [1] with respect to substrate. 
Figure 4.8: The Lineweaver-Burk analysis of [1] with respect to ATP. 
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A Lineweaver-Burk analysis was performed on the compound in order to better understand the 
binding mode of the compound. The data suggests that [1] may bind in an ATP-noncompetitive 
mode or possibly with mixed inhibition. Additionally, the substrate data is equally ambiguous 
with respect to compound [1]. (Figure 4.7, Figure 4.8) This is further illustrated with the KM 
plots for these analyses, provided in section Appendix C. With hopes to better illustrate the 
binding mode of compound [1], we evaluated the Lineweaver-Burk data using a Hanes analysis. 
This data is provided in Appendix D. Although the substrate data still is unclear, the ATP data 
may suggest an ATP-noncompetitive mode of binding. Overall, the ambiguity of this data leads 
us to believe that the compound is binding in an allosteric pocket on the protein.  
4.3.2.2: Cellular proliferation studies and [1] analog library 
 
 
Figure 4.9: The [1] analog library with IC50 data 
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Cellular proliferation studies were performed on the compound in a human breast 
cancer cell line, SK-BR-3 cells. However, [1] did not show any cell growth inhibition. Despite the 
inability for this compound to enter the cell, a library of seven analogs were synthesized or 
purchased in order to refine the scaffold and arrive at a compound that would be able to 
permeate the cell membrane. The compounds (Figure 4.9) were initially evaluated against wild 
type c-Src; unfortunately, not one of the compounds displayed any inhibitory activity against 
the kinase.  
Although not active in kinetic assays, the methyl ester analog of [1], [1c], was evaluated 
in a cellular proliferation study using SK-BR-3 cells. Following a 72-hour exposure to the cells, 
compound [1c] inhibited the growth of the SK-BR-3 cells with a GI50 of 22.5 µM. (Figure 4.10) It 
is assumed that [1c] acts as a prodrug of [1] as the methyl ester is cell permeable and become 
metabolized to the carboxylic acid containing [1] upon entering the cell.  
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Figure 4.10: The GI50 curve of compound [1c] against SK-BR-3 cells. 
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4.4: Conclusions  
Using a fragment library, we were able to discover a thiophene scaffold that is an 
inhibitor of the PTK, c-Src. The parent compound, [1] displays selectivity for c-Src over other 
similar PTKs, c-Abl and c-Hck. Additionally, compound [1] inhibits the clinically relevant T338M 
c-Src mutant (IC50 7.9 µM). Furthermore, Lineweaver-Burk data supports that this compound 
does not bind the PTK as an ATP-competitive manner, but in an allosteric pocket as our 
evaluation suggests ambiguous substrate inhibition data. Although the carboxylic acid 
containing parent compound does not enter cells, the methyl ester analog, [1c], of the 
compound inhibits the growth of a human breast cancer cell line with a GI50 of 23.5 µM.  
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 Although the protein tyrosine kinase, c-Src has been well-studied and investigated, 
there are still many characteristics that are unknown and undocumented. Herein lies the 
biggest challenge to the rational development of a selective substrate-competitive inhibitors. 
Despite being the first protein tyrosine kinase discovered, we do not have extensive knowledge 
of its substrate-binding region.  
 The principle motivations behind this collection of work were to elucidate a better 
understanding of the substrate-binding pocket of c-Src for future rational design of inhibitors to 
target the kinase. Using various approaches to develop series of compounds, we struggled to 
truly uncover any concrete binding trends. As witnessed with the biphenyl library of Chapter 2, 
we can note that despite having similar scaffolds, small molecule inhibitors targeting the 
substrate pocket can bind promiscuously and do not necessarily bind in a similar manner to one 
another. However, from our study on biphenyl containing compounds, we were encouraged to 
elucidate the (4-morpholino)biphenylethylacetamide (BiPH 65) as a low micromolar substrate-
competitive, ATP-noncompetitive inhibitor of c-Src. It is noteworthy to mention that this 
compound not only inhibits the kinase domain and physiologically relevant three domain forms 
of c-Src, it also can inhibit the clinically relevant T338M c-Src protein. Furthermore, we have not 
only shown selectivity for c-Src over other closely related or highly similar protein tyrosine 
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kinases: c-Abl and c-Hck, but we have also demonstrated the ability of BiPH 65 to inhibit cell 
growth of a human colon carcinoma cell line, HT-29, with a GI50 of 10.3 μM. From this intensive 
study of the biphenyl library, we were able to demonstrate the importance of our very 
specialized TR-FRET screen. Developed in our laboratory, these TR-FRET screens allowed us to 
not only characterize ATP-competitive binding compounds, but also, those compounds that 
bound the kinase in a substrate-competitive fashion simultaneously. The specialized TR-FRET 
assay provided a means to evaluate and characterize our compounds for a predicted binding 
mode quickly and efficiently. Without the work done previously in our lab by Dr. Bremmer on 
the development of this screen, we may not have arrived at our best compound, BiPH 65 as 
quickly.  
 Chapter 3 highlighted the struggles with the design and development of substrate-
competitive inhibitors. The motivations behind this project focused on the truncation of a 
peptidic inhibitor based on a natural substrate sequence to a small peptidomimetic compound 
to serve as a substrate-competitive inhibitor. However, from this study we observed that, 
although truncated from a larger peptidic inhibitor that binds to the substrate pocket of the 
kinase, the peptidomimetic compounds synthesized and evaluated were more promiscuous, 
and bound to other regions of the kinase as well. Despite the lack of success with this project, a 
good lesson was learned about this particular approach to the design of substrate-competitive 
inhibitors and the potential promiscuity of peptidomimetic compounds. We can conclude that 
compounds derived from peptide structures do not necessarily bind in the same manner as 
their larger counterparts. Furthermore, we also concluded that our general assay does not 
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provide a biased and specialized enough means by which to characterize substrate-competitive 
inhibitors.  
 Chapter 4 detailed our evaluation of a commercially available fragment library as we 
began a search for a new substrate-competitive scaffold on which to design new inhibitors. 
Although we were unable to elucidate a substrate-competitive inhibitor, our study revealed 
evidence of an allosteric inhibitor of c-Src, [1]. Although [1] is unable to inhibit the growth of a 
cancer cell line, we demonstrated that [1c], the methyl ester analog of [1], acts in a pro-drug 
fashion and inhibits the cell growth of the SK-BR-3 cells, a breast cancer cell line, with a GI50 of 
23.5 μM. The use of a biased screen in this study allowed us to better characterize and remove 
more ATP-competitive inhibitors than our general screen. However, even a biased screen did 
not fully allow us to easily find substrate-competitive binding compounds.  
 In order to fully characterize the compounds of interest developed in the projects 
discussed in chapters 2 and 4, obtaining crystal structures of the compound bound to the 
protein would surely aid in the understanding of the inhibitor compound’s interactions with c-
Src. This would conclusively confirm the substrate-competitive mode of binding of BiPH 65 as 
well as provide some insight as to where, exactly, the Maybridge fragment [1] is binding 
allosterically to the protein tyrosine kinase. Despite current laboratory efforts in these matters, 























Supplemental Information for Chapter 2 
 
A.1: General synthetic methods Unless otherwise noted, all reagents were obtained from 
commercially available sources and used without further purification. All 1H and 13C NMR 
spectra were measured with an Inova 500 spectrometer. Samples were taken in CDCl3 or 
DMSO-d6, spectra were referenced to chloroform peak. High resolution mass spectrometry 
(HRMS) was carried out by the University of Michigan Mass Spectrometry Facility (J. Windak, 
Director). 
A.2: Synthesis of compounds  
 
Synthesis of S1 
 
In a dried, round-bottom flask equipped with a stir bar, 4-bromophenethyl amine was added 
(0.500 mL, 3.22 mmol) and dissolved in 5.00 mL of Capmix A (80% Tetrahydrofuran, 10% Acetic 
Anhydride, 10% Pyridine). The solution was allowed to stir overnight at room temperature. The 
organics were removed under reduced pressure. The resulting oil was solubilized in ethyl 
acetate (20 mL), washed with 10% aqueous citrate (1 x 10 mL), followed by a wash with a brine 
solution (1 x 10 mL). The resulting organic layer was dried over anhydrous MgSO4 and filtered. 
The solvent was removed under reduced pressure to provide the crude product, which was 
purified via automated silica gel chromatography (Linear gradient of 0  10% methanol in 
DCM) to yield compound S1 as a white solid (696.5 mg, 90% yield) Spectral data. 1H NMR (500 
MHz, Chloroform-d) δ 7.45 – 7.37 (m, 2H), 7.08 – 7.01 (m, 2H), 5.77 (s, 1H), 3.44 (td, J = 7.0, 5.9 
Hz, 2H), 2.75 (t, J = 7.0 Hz, 2H), 1.91 (s, 3H). 13C NMR (500 MHz, Chloroform-d) δ 170.37, 137.95, 
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131.58, 130.51, 130.46, 120.23, 40.53, 35.02, 23.15, 19.55. HRMS-ESI (m/z): [M+H]+ calcd for 
C10H12BrNO 242.0175; found 242.0169. 
 
Synthesis of BiPH 47 
 
Synthesis of BiPH 47:  N-acetyltyramine (179 mg, 1.0 mmol) was dissolved in 5 mL anhydrous 
DMF. K2CO3 (138 mg, 1.0 mmol) was added followed by benzylbromide (0.13 mL, 1.1 mmol), 
and the reaction was heated at 60 C under N2 for 24 h.  The reaction was cooled to RT, diluted 
with 20 mL H2O, and extracted with EtOAc (3 x 20 mL).  The combined organic extracts were 
washed with brine, dried over MgSO4, and concentrated to give a colorless oil.  Purification via 
automated silica gel chromatography (Linear gradient of 1  10% MeOH in DCM) gave BiPH 47 
as a white crystalline solid (73 mg, 27% yield). Spectral data. 1H NMR (500 MHz, Chloroform-d) 
δ 7.47 – 7.29 (m, 5H), 7.15 – 7.07 (m, 2H), 6.96 – 6.89 (m, 2H), 5.48 – 5.44 (m, 1H), 5.05 (s, 2H), 
3.48 (td, J = 6.9, 5.8 Hz, 2H), 2.75 (t, J = 6.9 Hz, 2H), 1.94 (s, 3H).13C NMR (500 MHz, Chloroform-
d) δ 170.02, 157.50, 137.01, 131.13, 129.71, 128.60, 127.98, 127.48, 115.01, 77.30, 77.04, 









Synthesis of BiPH 50 
 
 
In a dried, round-bottom flask equipped with a stir bar, S1 (242 mg, 1 mmol), palladium (II) 
acetate (12 mg, 0.5 mmol), 2-(Dicyclohexylphosphino)biphenyl (35 mg, 0.1 mmol), and 
potatssium fluoride (174 mg, 3 mmol), were dissolved in anhydrous THF 5 mL). 3-
trifluoromethylphenyl boronic acid (228 mg, 1.2 mmol) was added and the contents of the flask 
were heated to 60°C in an oil bath and allowed to stir overnight. The reaction was quenched 
with water (20 mL) and was extracted with DCM (2 x 10 mL). The organic layer was washed with 
brine (1 x 10 mL) and dried over anhydrous MgSO4 and filtered. The solvent was removed under 
reduced pressure to provide the crude product, which was purified via automated silica gel 
chromatography (Linear gradient of 0  100% ethyl acetate in hexanes) to yield compound 
BiPH 50  as a white crystalline solid (41.8 mg, 14% yield) Spectral data. 1H NMR (500 MHz, 
Chloroform-d) δ 7.82 (td, J = 1.6, 0.8 Hz, 1H), 7.75 (dt, J = 7.7, 1.5 Hz, 1H), 7.63 – 7.52 (m, 4H), 
7.36 – 7.27 (m, 2H), 5.75 (s, 1H), 3.56 (td, J = 7.0, 5.8 Hz, 2H), 2.89 (t, J = 7.0 Hz, 2H), 1.97 (s, 3H). 
13C NMR (500 MHz, Chloroform-d) δ 170.25, 141.57, 138.91, 137.95, 131.24, 130.98, 130.24, 
129.40, 129.27, 128.72, 128.63, 127.36, 125.27, 123.90, 40.67, 35.30, 23.29. HRMS-ESI (m/z): 









Synthesis of BiPH 65 
 
 
In a dried, round-bottom flask equipped with a stir bar, S1 (242 mg, 1 mmol), palladium (II) 
acetate (12 mg, 0.05 mmol), 2-(Dicyclohexylphosphino)biphenyl (35 mg, 0.1 mmol), and 
potatssium fluoride (174 mg, 3 mmol), were dissolved in anhydrous THF (5 mL). 4-
morpholinophenyl boronic acid (248.4 mg, 1.2 mmol) was added and the contents of the flask 
were heated to 60°C in an oil bath and allowed to stir overnight. The reaction was quenched 
with water (20 mL) and was extracted with DCM (2 x 10 mL). The organic layer was washed with 
brine (1 x 10 mL) and dried over anhydrous MgSO4 and filtered. The solvent was removed under 
reduced pressure to provide the crude product, which was purified via automated silica gel 
chromatography (Linear gradient of 1  10% methanol in dichloromethane) to yield compound 
BiPH 65 as a brown solid (82.3 mg, 25% yield) Spectral data. 1H NMR (500 MHz, Chloroform-d) 
δ 7.54 – 7.39 (m, 3H), 7.34 – 7.16 (m, 1H), 7.10 – 7.03 (m, 1H), 7.02 – 6.84 (m, 3H), 5.48 (dd, J = 
14.7, 8.5 Hz, 1H), 3.90 – 3.81 (m, 4H), 3.50 (dtd, J = 30.4, 7.0, 5.9 Hz, 2H), 3.23 – 3.12 (m, 4H), 
2.80 (dt, J = 34.1, 6.9 Hz, 2H), 1.94 (d, J = 5.1 Hz, 3H). 13C NMR (500 MHz, Chloroform-d) δ 
170.08, 137.86, 137.10, 131.70, 130.48, 129.19, 129.13, 127.63, 127.20, 126.72, 120.36, 115.77, 
115.70, 66.94, 66.89, 49.35, 49.15, 40.64, 35.09, 23.32. HRMS-ESI (m/z): [M+H]+ calcd for 











Synthesis of S9. In a dried, round-bottom flask equipped with a stir bar, 4-bromophenethyl 
amine (0.390 mL, 2.5 mmol) was added and dissolved in DCM (10 mL). 4-fluorophenylsulfonyl 
chloride (535.2 mg, 2.75 mmol) and diisopropyl ethyl amine (0.87 mL, 5 mmol) were added last 
and the solution was allowed to stir overnight at room temperature. The organics were 
removed under reduced pressure. The resulting oil was solubilized in ethyl acetate (20 mL), 
washed with 10% aqueous citrate (1 x 10 mL), followed by a wash with a brine solution (1 x 10 
mL). The resulting organic layer was dried over anhydrous MgSO4 and filtered. The solvent was 
removed under reduced pressure to provide the crude product, which was purified via 
automated silica gel chromatography (Linear gradient of 0  10% methanol in DCM) to yield 
compound S9 as a yellow solid (758.8 mg, 84% yield) Spectral data. 1H NMR (500 MHz, 
Chloroform-d) δ 7.93 – 7.85 (m, 2H), 7.50 – 7.43 (m, 2H), 7.30 – 7.22 (m, 2H), 7.10 – 7.02 (m, 
2H), 4.81 (t, J = 6.3 Hz, 1H), 3.29 (q, J = 6.8 Hz, 2H), 2.83 (t, J = 7.0 Hz, 2H). 13C NMR (500 MHz, 
Chloroform-d) δ 221.47, 166.06, 165.87, 164.03, 160.33, 158.35, 137.93, 135.89, 133.38, 
130.55, 129.80, 129.72, 129.00, 125.60, 117.47, 117.27, 116.43, 116.25, 52.44, 44.10, 35.59. 






In a dried, round-bottom flask equipped with a stir bar, S9 (213 mg, 0.56 mmol), palladium (II) 
acetate (6.73 mg, 0.03 mmol), 2-(Dicyclohexylphosphino)biphenyl (21.02 mg, 0.06 mmol), and 
potatssium fluoride (105 mg, 1.8 mmol), were dissolved in anhydrous THF (5 mL). 4-COOMe, 2-F 
phenyl boronic acid (200 mg, 1.1 mmol) was added and the contents of the flask were heated 
to 60°C in an oil bath and allowed to stir overnight. The reaction was quenched with water (20 
mL) and was extracted with DCM (2 x 10 mL). The organic layer was washed with brine (1 x 10 
mL) and dried over anhydrous MgSO4 and filtered. The solvent was removed under reduced 
pressure to provide the crude product, which was purified via automated silica gel 
chromatography (Linear gradient of 0  100% ethyl acetate in hexanes) to yield compound 
BiPH 85 as a tan crystalline solid (40 mg, 17% yield) Spectral data. 1H NMR (500 MHz, 
Chloroform-d) δ 7.99 – 7.84 (m, 4H), 7.58 – 7.51 (m, 3H), 7.28 – 7.18 (m, 4H), 4.58 (t, J = 6.3 Hz, 
1H), 4.01 (s, 3H), 3.34 (q, J = 6.7 Hz, 2H), 2.90 (t, J = 6.9 Hz, 2H).13C  NMR (500 MHz, CDCl3): δ 
221.47, 166.06, 165.87, 164.03, 160.33, 158.35, 137.93, 135.89, 133.38, 130.55, 129.80, 129.72, 
129.00, 125.60, 117.47, 117.27, 116.43, 116.25, 52.44, 44.10, 35.59. HRMS-ESI (m/z): [M+Na]+ 










Synthesis of BiPH 108 
 
 
Synthesis of S2 and S3. Into a plastic, microwave peptide vessel, Rink Amide resin (639 mg, 0.1 
mmol) was added and swollen with n-methyl-2-pyrrolidone (7 mL). The vessel was placed on a 
shake plate for 1 hour at room temperature. Following this period, the solvent in the vessel was 
evacuated and to it, deprotection solution (7 mL, 20% piperidine, 0.15 M HOBt in NMP) was 
added. Again, the vessel was placed on a shake plate for 1 hour at room temperature and 
subsequently the solvent was evacuated and the beads were washed with NMP (3 x 10 mL). 
The resin beads were evaluated for complete Fmoc deprotection through the use of the Kaiser 
test.1 The resin beads were washed with DCM (3 x 5 mL) and dried.  A solution of Fmoc-(4-
Br)phenylalanine-OH (560 mg, 1.2 mmol) and HBTU (500 mg, 1.3 mmol) and activator solution 
(10% Diisopropylethylamine in NMP, 4 mL) was prepared and added to another vessel 
containing deprotected rink amide resin beads (200 mg of deprotected beads). The vessel was 
allowed to shake at room temperature overnight. Upon solvent evacuation and the washing of 
the beads (NMP, 3 x 10 mL), the resin beads were evacuated with the Kaiser test to insure 
complete coupling of the amino acid to the resin beads, arriving at compound S2. Lastly, the 
beads were deprotected, Kaiser tested, and dried as previously described to arrive at S3.  
 
Synthesis of S4. To the resin beads of compound S3, a solution of phenyl isocyanate (5% in 4 mL 
of activator solution) was added and allowed to shake at room temperature overnight. The 
vessel was then evacuated, washed with NMP (3 x 5 mL) and evaluated by Kaiser Test to ensure 
complete coupling of the phenyl isocyanate. The beads were subsequently rinsed with DCM (3 x 




Synthesis of compound S5. The resin beads containing compound S4 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 4-methoxyphenyl boronic 
acid (304 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S5 on resin. 
Synthesis of BiPH 108. Compound S5 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 108 as a 
white crystalline solid (2 mg, < 1% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.68 (s, 
1H), 7.64 – 7.49 (m, 5H), 7.37 – 7.29 (m, 2H), 7.29 – 7.16 (m, 2H), 7.14 (d, J = 2.0 Hz, 1H), 7.03 – 
6.96 (m, 2H), 6.91 – 6.84 (m, 1H), 6.30 (d, J = 8.1 Hz, 1H), 4.46 (td, J = 7.8, 5.1 Hz, 1H), 3.78 (s, 
3H), 3.04 (dd, J = 13.8, 5.2 Hz, 1H), 2.86 (dd, J = 13.8, 7.6 Hz, 1H). 13C NMR (500 MHz, DMSO-d6) 
δ 173.81, 159.17, 157.07, 155.00, 140.78, 138.58, 132.80, 130.32, 129.12, 127.99, 126.28, 
121.51, 117.86, 114.77, 55.59, 54.05, 14.45. HRMS-ESI (m/z): [M+H]+ calcd for C23H23N3O3 













Synthesis of BiPH 101 
 
 
Synthesis of S19. To the resin beads of compound S3 (200 mg), a solution of Ac-Ala-OH (131 mg, 
1 mmol) and HBTU (380 mg, 1.0 mmol) in 4 mL activator solution was added and allowed to 
shake at room temperature overnight. The vessel was then evacuated, washed with NMP (3 x 5 
mL) and evaluated by Kaiser Test to ensure complete coupling. The beads were subsequently 
rinsed with DCM (3 x 5 mL) and dried arriving at compound S19 on resin. 
 
Synthesis of compound S20. The resin beads containing compound S19 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 4-methoxyphenyl boronic 
acid (304 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S20 on resin. 
 
Synthesis of BiPH 101. Compound S20 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 101 as a 
white crystalline solid (2 mg, <1% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.02 (dd, 
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J = 7.9, 4.5 Hz, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.52 (dt, J = 38.4, 8.3 Hz, 6H), 7.25 (dd, J = 18.0, 7.6 
Hz, 2H), 7.07 – 6.96 (m, 2H), 4.40 (dtd, J = 18.7, 9.6, 9.1, 5.0 Hz, 1H), 4.15 (q, J = 7.9, 7.4 Hz, 1H), 
3.77 (s, 4H), 3.30 (s, 3H), 3.00 (ddd, J = 25.0, 13.9, 4.8 Hz, 1H), 2.88 – 2.79 (m, 1H), 1.84 – 1.71 
(m, 3H), 1.09 (d, J = 6.9 Hz, 3H).13C NMR (500 MHz, DMSO-d6) δ 170.39, 170.28, 159.16, 144.94, 
136.68, 132.77, 130.18, 127.99, 126.21, 114.77, 62.47, 55.60, 54.26, 40.46, 25.42, 23.02, 18.20, 
14.73.HRMS-ESI (m/z): [M+Na]+ calcd for C21H25N3O4 406.1737; found 406.1746. 
 
 




Synthesis of S13. To the resin beads of compound S3 (200 mg), a solution of benzoic acid (200 
mg, 1.64 mmol) and HBTU (380 mg, 1.0 mmol) in 4 mL activator solution was added and 
allowed to shake at room temperature overnight. The vessel was then evacuated, washed with 
NMP (3 x 5 mL) and evaluated by Kaiser Test to ensure complete coupling. The beads were 
subsequently rinsed with DCM (3 x 5 mL) and dried arriving at compound S13 on resin. 
 
Synthesis of compound S14. The resin beads containing compound S13 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 3-chlorophenyl boronic 
acid (312 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
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water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S14 on resin. 
 
Synthesis of BiPH 142. Compound S14 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 142 as a 
white crystalline solid (2 mg, <1% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J 
= 8.4 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.63 – 7.56 (m, 1H), 7.56 – 7.30 (m, 8H), 7.14 (d, J = 2.2 Hz, 
1H), 4.68 (m, 1H), 3.16 (dd, J = 13.8, 4.1 Hz, 1H), 3.06 (dd, J = 13.8, 10.7 Hz, 1H). 13C NMR (500 
MHz, DMSO-d6) δ 173.79, 166.81, 140.07, 138.71, 138.63, 136.99, 136.87, 134.62, 131.94, 
131.72, 131.69, 130.28, 129.44, 129.39, 128.60, 127.91, 127.88, 55.10, 40.30, 37.30, 14.38. 
HRMS-ESI (m/z): [M+Na]+ calcd forC22H19ClN2O2 401.1027; found 401.1020. 
 
 
Synthesis of BiPH 230 
  
 
Synthesis of S15. In a dried, round-bottom flask equipped with a stir bar, 4-bromo-2-
fluorophenyl ethyl amine (55 mg, 0.253 mmol) was solubilized in dioxane (10 mL). To this 
solution, boc anhydride (61 mg, 0.278 mmol) and NaOH (0.100 mL, 0.6 M) were added. The 
reaction was allowed to stir overnight at room temperature. Following this, the solvent was 
removed under reduced pressure. The crude product was dissolved in ethyl acetate (10 mL) and 
washed with water (2 x 10 mL). The organic layer was dried over anhydrous MgSO4 and filtered. 
The solvent was removed under reduced pressure to provide the crude product, which was 
purified via automated silica gel chromatography (Linear gradient of 5  40% ethyl acetate in 
hexanes) to yield compound S15 as a white solid (53.9 mg, 67% yield) Spectral data. 1H NMR 
(500 MHz, Chloroform-d) δ 7.22 (ddd, J = 9.5, 4.7, 2.0 Hz, 2H), 7.07 (t, J = 8.1 Hz, 1H), 4.55 (s, 
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1H), 3.35 (q, J = 7.1 Hz, 2H), 2.80 (t, J = 6.7 Hz, 2H), 1.42 (s, 9H).13C  NMR (500 MHz, Chloroform-
d): δ 162.08, 160.09, 155.79, 132.26, 127.37, 125.08, 120.35, 119.09, 118.89, 79.39, 40.34, 





Synthesis of BiPH 230. In a dried, round-bottom flask equipped with a stir bar, S15 (25.8 mg, 
0.081 mmol) was solubilized in DMF (1 mL). To this solution, 
Palladium(II)bis(triphenylphosphine) dichloride (11.4 mg, 0.016 mmol), potassium carbonate 
(33.8 mg, 0.244 mmol), 3,4-dimethoxyphenyl boronic acid (30 mg, 0.163 mmol) was added and 
the contents of the flask were heated to 70°C in an oil bath and allowed to stir for 4 days. The 
solvent was removed under reduced pressure to provide the crude product, (230 mg, brown 
oil) which was promptly used without further purification. The BOC-protected crude brown oil 
was solubilized in a solution of HCl in dioxane (10 mL, 4 M) and was allowed to stir for 2 hours. 
The solvent was removed under reduced pressure to provide the crude product, which was 
purified via reverse-phase chromatography (linear gradient of 5  95% CH3CN (0.1% HOAc) in 
H2O (0.1% HOAc)) to yield BiPH 230 as a white solid, trifluroacetic acid salt (1.71 mg, 7.4% 
yield). Spectral data. 1H NMR (500 MHz, Chloroform-d) δ 8.21 (s, 2H), 7.26 (s, 2H), 7.11 – 6.98 
(m, 3H), 6.90 (d, J = 8.1 Hz, 1H), 3.98 (s, 3H), 3.94 – 3.88 (m, 3H), 3.25 (s, 2H), 3.09 (s, 2H). 13C 
NMR (500 MHz, Chloroform-d) δ 160.61, 153.24, 135.99, 134.57, 131.29, 129.48, 122.76, 
121.07, 119.30, 117.50, 111.44, 110.11, 107.17, 55.94, 39.70, 27.48. 19F NMR (376 MHz, DMSO-
d6) δ -73.52 , -118.37 (t, J = 9.7 Hz). HRMS-ESI (m/z): [M+H]









Synthesis of BiPH 240 
 
 
Synthesis of S6. In a dried, round-bottom flask equipped with a stir bar, 4-bromophenethyl 
amine (0.390 mL, 2.5 mmol) was added and dissolved in DCM (10 mL). Benzoyl chloride (0.32 
mL, 2.75 mmol) and diisopropyl ethyl amine (0.87 mL, 5 mmol) were added last and the 
solution was allowed to stir overnight at room temperature. The organics were removed under 
reduced pressure. The resulting oil was solubilized in ethyl acetate (20 mL), washed with 10% 
aqueous citrate (1 x 10 mL), followed by a wash with a brine solution (1 x 10 mL). The resulting 
organic layer was dried over anhydrous MgSO4 and filtered. The solvent was removed under 
reduced pressure to provide the crude product, which was purified via automated silica gel 
chromatography (Linear gradient of 0  10% methanol in DCM) to yield compound S6 as a grey 
crystalline solid (620 mg, 82% yield) Spectral data 1H NMR (500 MHz, Chloroform-d) δ 7.72 – 
7.66 (m, 2H), 7.53 – 7.37 (m, 5H), 7.14 – 7.07 (m, 2H), 6.24 – 6.18 (m, 1H), 3.68 (td, J = 6.9, 5.9 
Hz, 2H), 2.89 (t, J = 6.9 Hz, 2H). 13C NMR (500 MHz, Chloroform-d) δ 221.67, 167.56, 137.93, 
134.45, 131.73, 131.52, 130.55, 128.60, 126.83, 120.41, 81.61, 41.02, 35.15, 19.51, 19.49. 






Synthesis of BiPH 240. In a dried, round-bottom flask equipped with a stir bar, S6 (100 mg, 
0.330 mmol), palladium (II) acetate (4 mg, 0.017 mmol), 2-(Dicyclohexylphosphino)biphenyl (12 
mg, 0.033 mmol), and potatssium fluoride (58 mg, 0.99 mmol), were dissolved in anhydrous 
THF (4 mL). 4-morpholinophenyl boronic acid (87 mg, 0.40 mmol) was added and the contents 
of the flask were heated to 60°C in an oil bath and allowed to stir overnight. The reaction was 
quenched with water (20 mL) and was extracted with DCM (2 x 10 mL). The organic layer was 
washed with brine (1 x 10 mL) and dried over anhydrous MgSO4 and filtered. The solvent was 
removed under reduced pressure to provide the crude product, which was purified via 
automated silica gel chromatography (Linear gradient of 7  70% ethyl acetate in hexanes) to 
yield compound BiPH 240 as a white solid (40 mg, 30% yield) Spectral data. 1H NMR (500 MHz, 
Chloroform-d) δ 7.71 (d, J = 7.4 Hz, 2H), 7.60 – 7.29 (m, 8H), 7.29 – 7.12 (m, 2H), 6.92 (dd, J = 
8.4, 2.6 Hz, 1H), 6.21 – 6.15 (m, 1H), 4.41 (q, J = 8.1 Hz, 2H), 3.76 (q, J = 6.6 Hz, 2H), 2.99 (t, J = 
6.9 Hz, 2H). 13C NMR (500 MHz, Chloroform-d) δ 167.52, 157.79, 142.73, 138.78, 138.52, 
134.60, 131.48, 130.07, 129.33, 128.60, 127.43, 126.81, 121.28, 113.89, 113.37, 77.28, 77.03, 
76.77, 67.14, 66.07, 65.78, 41.12, 35.37.  HRMS-ESI (m/z): [M+H]+ calcd for C23H20F3NO2 















Synthesis of S10. In a dried, round-bottom flask equipped with a stir bar, 4-bromo, 2-
fluorophenethyl amine (67.0 mg, 0.31 mmol) was added and dissolved in anhydrous THF (8 mL). 
Ac-Ile-OH (45 mg, 0.26 mol), PyBop (161.3 mg, 0.31 mmol) and n-methylmorpholine (0.860 mL, 
0.78 mmol) were added and the solution was allowed to stir overnight at room temperature. 
The organics were removed under reduced pressure. The resulting oil was solubilized in DCM 
(20 mL) and washed with a brine solution (1 x 10 mL). The resulting organic layer was dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to provide 
the crude product, which was purified via reverse-phase chromatography (linear gradient of 5 
 95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield S10 (17.7 mg, 0.05 mmol, 15% yield). 
Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.05 (t, J = 5.9 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 
7.46 (dd, J = 9.9, 2.0 Hz, 1H), 7.31 (dd, J = 8.4, 2.0 Hz, 1H), 7.23 (t, J = 8.1 Hz, 1H), 4.05 (t, J = 8.3 
Hz, 1H), 3.34 – 3.19 (m, 2H), 2.70 (td, J = 7.1, 6.6, 2.2 Hz, 2H), 2.08 (s, 1H), 1.84 (d, J = 8.8 Hz, 
3H), 1.61 (ddd, J = 16.7, 11.5, 7.7 Hz, 1H), 1.30 (dtd, J = 15.1, 7.5, 3.5 Hz, 1H), 1.06 – 0.93 (m, 
1H), 0.82 – 0.68 (m, 6H). 13C NMR (500 MHz, DMSO-d6) δ 171.53, 169.46, 148.35, 133.36, 
127.72, 118.94, 118.74, 109.99, 57.30, 36.77, 25.42, 24.70, 22.93, 15.75, 14.72, 11.44. HRMS-







Synthesis of BiPH 248. In a dried, round-bottom flask equipped with a stir bar, S10 (6.5 mg, 
0.020 mmol), Palladium(II)bis(triphenylphosphine) dichloride (1.4 mg, 0.002 mmol), and sodium 
carbonate (1 mL,2 M solution), were dissolved in a 1:1 solution of ethanol:toluene (5 mL). 4-
morpholinophenyl boronic acid (6.1 mg, 0.04 mmol) was added and the contents of the flask 
were heated to 80°C in an oil bath and allowed to stir overnight. The solvent was removed 
under reduced pressure to provide the crude product, which was purified via reverse-phase 
chromatography (linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield 
BiPH 248 (1.2 mg, 18% yield) as a white solid. Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 
8.07 (t, J = 5.8 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H), 7.62 (d, J = 8.2 Hz, 2H), 7.43 – 7.34 (m, 2H), 7.31 
(t, J = 8.0 Hz, 1H), 7.01 (d, J = 8.3 Hz, 2H), 4.08 (t, J = 8.3 Hz, 1H), 3.79 (s, 3H), 3.37 (dd, J = 12.8, 
6.9 Hz, 2H), 2.76 (t, J = 7.0 Hz, 2H), 1.85 (d, J = 9.3 Hz, 3H), 1.64 (d, J = 8.2 Hz, 1H), 1.41 – 1.30 
(m, 1H), 1.02 (dt, J = 15.2, 7.7 Hz, 1H), 0.77 (dp, J = 16.8, 6.5, 5.6 Hz, 6H). 13C NMR (500 MHz, 
DMSO-d6) δ 171.50, 169.46, 160.58, 159.58, 133.85, 132.00, 128.13, 124.61, 124.48, 122.19, 
114.82, 113.05, 112.87, 57.33, 55.64, 55.36, 38.96, 36.84, 28.60, 24.73, 22.94, 15.78, 11.46. 

















Synthesis of S17. To the resin beads of compound S3 (400 mg), a solution of m-toluic acid (136 
mg, 1.0 mmol, and HBTU (380 mg, 1.0 mmol) in 4 mL activator solution was added and allowed 
to shake at room temperature overnight. The vessel was then evacuated, washed with NMP (3 
x 5 mL) and evaluated by Kaiser Test to ensure complete coupling. The beads were 
subsequently rinsed with DCM (3 x 5 mL) and dried arriving at compound S17. 
 
Synthesis of compound S18. The resin beads containing compound S17 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 4-methoxyphenyl boronic 
acid (304 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S18 on resin. 
 
Synthesis of BiPH 250. Compound S18 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
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(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 250 (2.0 mg, 
<1% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.44 (d, J = 8.4 Hz, 1H), 7.66 – 7.42 
(m, 6H), 7.41 – 7.24 (m, 4H), 7.11 (d, J = 2.5 Hz, 2H), 7.01 – 6.94 (m, 2H), 4.66 (ddd, J = 10.5, 8.4, 
4.2 Hz, 1H), 3.77 (s, 3H), 3.20 – 3.08 (m, 1H), 3.08 – 2.97 (m, 1H), 2.34 (s, 3H). 13C NMR (500 
MHz, DMSO-d6) δ 173.82, 166.76, 159.14, 138.10, 137.86, 137.53, 134.54, 132.73, 132.24, 
128.51, 128.40, 127.98, 126.22, 124.99, 114.72, 55.58, 55.16, 37.27, 21.39. HRMS-ESI (m/z): 
[M+H]+ calcd for C24H24N2O3 389.1860; found 389.1862. 
 
 




Synthesis of S7. To the resin beads of compound S3 (400 mg), a solution of p-toluic acid (136 
mg, 1.0 mmol, and HBTU (380 mg, 1.0 mmol) in 4 mL activator solution was added and allowed 
to shake at room temperature overnight. The vessel was then evacuated, washed with NMP (3 
x 5 mL) and evaluated by Kaiser Test to ensure complete coupling. The beads were 
subsequently rinsed with DCM (3 x 5 mL) and dried arriving at compound S7. 
 
Synthesis of compound S8. The resin beads containing compound S7 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 4-methoxyphenyl boronic 
acid (304 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
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minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S8 on resin. 
 
Synthesis of BiPH 259. Compound S8 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 259 as a 
white crystalline solid (2 mg, <1% yield). Spectral data 1H NMR (500 MHz, DMSO-d6) δ 8.43 (d, J 
= 8.4 Hz, 1H), 7.76 – 7.68 (m, 2H), 7.59 – 7.47 (m, 4H), 7.41 – 7.34 (m, 2H), 7.28 – 7.21 (m, 2H), 
7.11 (s, 2H), 7.01 – 6.94 (m, 2H), 4.64 (ddd, J = 10.5, 8.3, 4.1 Hz, 1H), 3.77 (s, 3H), 3.11 (dd, J = 
13.7, 4.2 Hz, 1H), 3.01 (dd, J = 13.7, 10.5 Hz, 1H), 2.33 (s, 3H).. 13C NMR (500 MHz, DMSO-d6) δ 
173.86, 164.47, 158.07, 131.75, 130.17, 130.13, 129.18, 129.14, 128.01, 127.98, 127.89, 126.22, 
114.72, 106.15, 62.52, 55.59, 25.47, 14.76. HRMS-ESI (m/z): [M+H]+ calcd for C24H24N2O3 
389.1860; found 389.1857. 
 
 




Synthesis of S11. To the resin beads of compound S3 (200 mg), a solution of 2-aminobenzoic 
acid (200 mg, 1.46 mmol) and HBTU (380 mg, 1.0 mmol) in 4 mL activator solution was added 
and allowed to shake at room temperature overnight. The vessel was then evacuated, washed 
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with NMP (3 x 5 mL) and evaluated by Kaiser Test to ensure complete coupling. The beads were 
subsequently rinsed with DCM (3 x 5 mL) and dried arriving at compound S11 on resin. 
 
Synthesis of compound S12. The resin beads containing compound S11 were transferred to a 
dried, glass microwave vessel equipped with a stir bar. To this vessel, 4-methoxyphenyl boronic 
acid (304 mg, 2.0 mmol), sodium carbonate (212 mg, 2.0 mmol), 
tetrakis(triphenylphosphine)palladium (0) (24 mg, 0.021 mmol) were added. A solvent mixture 
of ethanol:water:diglycol methyl ether (2:1:10) was subsequently added and the reaction vessel 
was placed into a CEM microwave synthesizer. The reaction was heated to 140 °C for 20 
minutes at 150 W of power. After cooling, the reaction mixture was washed with deionized 
water (~50 mL), NMP (3 x 10 mL), Methanol (3 x 10 mL), Diglycol methyl ether (3 x 10 mL), and 
DCM (3 x 10 mL), resulting in the preparation of compound S12 on resin. 
Synthesis of BiPH 264. Compound S12 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropyl silane 0.1 mL) for 1 hour with 
intermittent stirring. The resulting solution was filtered, collected and the solvent was removed 
under reduced pressure. The resulting oil was purified via reverse-phase chromatography 
(linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield BiPH 264 as a tan 
solid (3 mg, <1% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 8.25 (d, J = 8.3 Hz, 1H), 
7.60 – 7.47 (m, 6H), 7.42 – 7.34 (m, 2H), 7.24 – 7.07 (m, 2H), 7.03 – 6.95 (m, 2H), 6.69 (dd, J = 
8.1, 1.3 Hz, 1H), 6.57 (t, J = 7.4 Hz, 1H), 4.60 (ddd, J = 10.5, 8.2, 4.2 Hz, 1H), 3.78 (s, 3H), 3.10 
(dd, J = 13.8, 4.2 Hz, 1H), 3.01 (dd, J = 13.7, 10.5 Hz, 1H). 13C NMR (500 MHz, DMSO-d6) δ 
174.01, 169.14, 159.14, 153.41, 137.62, 132.24, 130.11, 128.92, 128.88, 128.00, 126.25, 118.77, 
116.82, 114.78, 114.75, 114.72, 62.45, 55.58, 14.71. HRMS-ESI (m/z): [M+Na]+ calcd for 
C23H23N3O3 412.1632; found 412.1635. 
 










































































































































































































































































































































A.5: Biochemical characterization 
General procedure for TR-FRET evaluation of inhibitor binding. The TR-FRET assay described 
here is adapted from a LanthaScreen© Eu Kinase Binding Assay protocol set forth by 
Invitrogen.3,4 Reaction volumes of 50 µL were used in 384-well plates. 1 µL of inhibitor stock (5 
mM) to wells, save 1 DMSO control well. 600 µL of Buffer F mix were prepared (3 µL of 1 µM 
enzyme with 6x His-Tag, 4 µL of 300 µM Eu3+ antibody, 1.5 µL of 40 µM probe in DMSO, 591.5 
µL Buffer F) and 49 µL of the Buffer F mix were added to the wells. The plate was then spun 
down for 30 seconds at 4000 rpm to remove bubbles from wells. The plate was incubated for 
30 minutes in the dark. Reactions had final concentrations of 5 nM enzyme with 6x His-Tag, 2 
nM Eu3+ antibody, 100 nM ATP-binding probe or 1 nM bisubstrate-binding probe, 100 mM NaCl, 
50 mM Tris buffer pH 8, and 0.1% BSA. Reaction progress was monitored at 620 nm and 665 nm 
(ex. 460 nm) at 30°C. Percent fluorescence data was evaluated for each compound against each 
probe. Compounds were selected for further evaluation based on their ability to outcompete 
the bisubstrate probe (fluorescence 50% or less) while not outcompeting the ATP probe 












c-Src Optimal Sequence 
N-term Label with Cy5 
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General procedure for determination of inhibitor Ki. A continuous fluorescence assay
5 was 
used to determine Ki. Reaction volumes of 100 µL were used in 96-well plates. 85 µL of enzyme 
in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution (final 
concentrations typically 1000, 500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9 and 0 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)5 solution 
(1.8 mM in DMSO) was added. The reaction was initiated with 10 µL of ATP (10 mM in water), 
and reaction progress was immediately monitored at 405 nm (ex. 340 nm) for 10 minutes. 
Reactions had final concentrations of 30 nM enzyme, 45 µM peptide substrate, 1000 µM ATP, 
100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100. The initial rate 
data collected was used for determination of Ki values. For Ki determination, the kinetic values 
were obtained directly from nonlinear regression of substrate-velocity curves in the presence of 
various concentrations of the inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – 
LogEC50), X = log(concentration) and Y = binding; was used in the nonlinear regression. 
 
Analytical data for c-Src Kinase Domain Ki determination. Each inhibitor Ki value was 


































Average IC50: > 1000 μM 
 















































Average IC50: 60.36 ± 31.2 μM 
 





















































Average IC50: 191.5 ± 30.6 μM 
 
 


















































Average IC50: 218.4 ± 97.2 μM 
 




















































Average IC50: 74.1 ± 3.3 μM 
 
 



















































Average IC50: 97.4 ± 20.9 μM 
 




















































Average IC50: 378.0 ± 14.5 μM 
 

























Average IC50: 181.7 ± 10.5 μM 
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Analytical data for c-Src T341M Ki determination. Each inhibitor Ki value was determined using 
two independent experiments, a representative inhibition curve is shown. 
 
























Average IC50: > 1000 μM 
 
 




















































Average IC50: 26.4 ± 12.6 μM 
 
 




















































Average IC50: 217.9 ± 39.0 μM 
 



















































Average IC50: 333.6 ± 23.5 μM 
 
 
























































Average IC50: 77.6 ± 16.3 μM 
 

















































Average IC50: 28.0 ± 2.7 μM 
 




















































Average IC50: 329.5 ± 207.0 μM 
 
Analytical data for c-Src 3 Domain Ki determination. Each inhibitor Ki value was determined 
using two independent experiments, a representative inhibition curve is shown. 
 
































































Average IC50: 545.3 ± 627.0 μM 
 













































 Average IC50: 61.5 ± 75.0 μM 
 



















































Average IC50: 636.5 ± 545.3 μM 
 
 













































Average IC50: > 1000 μM 
 
 




























































Average IC50: 6.9 ± 0.2 μM 
 























































Average IC50: 150.0 ± 33.9 μM 
Analytical data for c-Src Kinase domain Ki determination at high [ATP] (5 mM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 













































Average IC50: 80.3 ± 43.3 μM 
 




















Average IC50: 85.4 ± 8.0 μM 
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Analytical data for c-Src Kinase domain Ki determination at low [ATP] (100 μM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 
 
























































Average IC50: 63.7 ± 5.8 μM 
 
 




















Average IC50: 83.6 ± 27.0 μM 
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Analytical data for c-Src Kinase domain Ki determination at high [substrate] (500 μM final 
concentration, 1 mM ATP concentration). Each inhibitor Ki value was determined using at least 
four independent experiments; a representative inhibition curve is shown. 
 





















































Average IC50: 40.2 ± 0.5 μM 
 




















Average IC50: 336.4 ± 44.5 μM 
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Analytical data for c-Abl Ki determination. Each inhibitor Ki value was determined using four 
independent experiments, a representative inhibition curve is shown. 
 









































Analytical data for c-Hck Ki determination. Each inhibitor Ki value was determined using four 
independent experiments, a representative inhibition curve is shown. 
 
























Average IC50 > 500 μM 
 
 
General procedure for ATP Lineweaver-Burk analysis of inhibitor. A continuous fluorescence 
assay5 was used to determine KM. Reaction volumes of 100 µL were used in 96-well plates. 85 
µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution 
(fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was then added. 2.5 µL 
of a substrate peptide (“compound 3” as described in Wang et al)5 solution (1.8 mM in DMSO) 
was added. The reaction was initiated with 10 µL of ATP (Two-fold dilutions, final 
concentrations: 5mM  0 in water), and reaction progress was immediately monitored at 405 
nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 µM 
peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-
100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of ATP. The equation Y = 
(Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 
used in the nonlinear regression.  
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Analytical data for c-Src Kinase Domain ATP Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
K M fo r  A T P  v s . B iP H  6 5
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General procedure for Substrate Lineweaver-Burk analysis of inhibitor. A continuous 
fluorescence assay5 was used to determine KM. Reaction volumes of 100 µL were used in 96-
well plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)5 solution 
(Final concentrations: 500 µM  0 in DMSO) was added. The reaction was initiated with 10 µL 
of ATP (Final concentration 1 mM in water), and reaction progress was immediately monitored 
at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 
µM peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton 
X-100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of substrate. The equation Y 
= (Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 




Analytical data for c-Src Kinase Domain Substrate Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
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A.5: Cancer cell growth inhibition assays 
General procedure:  
1. Cell culture and seeding:  Cells are dispersed from flasks and collected by centrifugation 
(125xg for 5 minutes at room temperature). An aliquot of the resuspended cells is mixed 
with trypan blue solution and the cell number is quantified using a hemacytometer. In 
general, depending on the growth rate of the untreated cells, the cells will be plated at 
5.0 – 7.5 x 103 cells per well. 100 µL of the cell mixture will be added to each well so the 
concentration should be 10X the cells per well in cells per mL. The cells are plated into 
sterile, clear bottom 96 well plates and cultured under normal growth conditions 
overnight prior to dosing with compound. 
2. Dosing: The 100% DMSO compound stocks need to be prepared to 100X the final 
concentration that is desired in the assay. 3 µL of the DMSO stock solution is then added 
to 297 µL of the cell growth media to give a DMSO concentration of 1%. The cell media 
is removed by aspiration for adherent cells and replaced with 100 µL per well of the cell 
growth media containing the compound. In general each compound concentration is 
dosed in triplicate wells. The plates are returned to normal culture conditions for 24 – 
72 hours.  
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3. Assay: After the required incubation period the plates are removed from the incubator 
and 10 µL per well of WST-1 reagent is added. The plates are returned to the incubator 
and the color change is visually monitored for 0.5 – 2 hours. When sufficient color 
change has occurred the plates are shaken on a plate shaker for 60 seconds and read in 
the appropriate plate reader.  
4. Data Analysis: The reference absorbance reading is subtracted from the formazan 
absorbance and the data is plotted as a percentage of the vehicle (1% DMSO alone). 
Data analysis and curve fitting was performed using Graphpad Prism. For each cell line, 
there were n = 3 data points for each concentration. Each dose response curve was 
performed at least twice, providing n ≥ 6 for each data point. 
BiPH 65 HT-29:  
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Supplemental Information for Chapter 3 
B.1: General Synthetic Methods Unless otherwise noted, all reagents were obtained from 
commercially available sources and used without further purification. All 1H and 19F NMR 
spectra were measured with a Varian 400 MHz spectrometer. Samples were taken in CDCl3 or 
DMSO-d6, spectra were referenced to chloroform peak.  
B.2: Synthesis of Compounds  
Fmoc-(4F)Tyrosine-OH amino acid 
 
The Fmoc-(4F)Tyrosine amino acid was prepared and purified via methods set forth by Wang, et al.1  
IV-sms-80 
 
In a dried, round-bottom flask equipped with a stir bar, and under nitrogen atmosphere, Fmoc-
(4F)Tyrosine-OH (0.100 g, 0.194 mmol) was dissolved in 5 mL of dichloromethane. To this, N,N’-
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dicyclohexylcarbodiimide (0.025 mL, 0.162 mmol), HOBT (0.021 g, 0.162 mmol), and DIEA 
(0.057 mL, 0.324 mmol) were added at 0°C and the reaction mixture was allowed to stir for 45 
minutes before adding aniline (0.015 mL, 0.162 mmol). The reaction was allowed to stir 
overnight for 18 hours. The solvent was removed under reduced pressure and the resulting 
crude product was solubilized in ethyl acetate (50 mL) and washed with water (1 x 50 mL) 
followed by a wash with a brine solution (1 x 50 mL). The resulting organic layer was dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to afford the 
crude allyl protected product, which was purified via automated silica gel chromatography 
(Linear gradient of 7  60% ethyl acetate in hexanes) to yield the allyl protected intermediate 
product as a white crystalline solid (0.050 g, 52.3% yield). Removal of the allyl protecting groups 
subsequently followed, as the allyl protected intermediate (0.050 g, 0.085 mmol) was dissolved 
in 5 mL of dichloromethane. To this, tetrakis(triphenylphosphine)palladium(0) (0.005 g, 0.004 
mmol) and phenylsilane (0.021 mL, 0.17 mmol) were added and the reaction was allowed to stir 
overnight for 18 hours at room temperature. The reaction mixture was washed with a solution 
of 10% aqueous citrate (2 x 20 mL) and the resulting organic layer was dried with anhydrous 
MgSO4 and filtered. The solvent was removed under reduced pressure to afford the crude IV-
sms-80 product which was purified via automated silica gel chromatography (Linear gradient of 
0  10% methanol in dichloromethane) as well as by reverse-phase chromatography (linear 
gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield IV-sms-80 as a crystalline 
solid (7.3 mg, 15.6% yield). Spectral data. 1H NMR (500 MHz, DMSO-d6) δ 11.24 (s, 1H), 9.94 (s, 
1H), 7.88 (d, J = 7.7 Hz, 3H), 7.71 (d, J = 7.6 Hz, 2H), 7.49 (d, J = 7.9 Hz, 2H), 7.41 (t, J = 7.5 Hz, 
2H), 7.30 (dd, J = 10.0, 4.0 Hz, 4H), 7.11 – 7.01 (m, 1H), 4.41 (q, J = 7.6 Hz, 1H), 4.29 (d, J = 8.2 
Hz, 1H), 4.26 – 4.14 (m, 2H), 3.11 (s, 1H), 2.99 (d, J = 1.9 Hz, 1H), contains solvent peaks. 19F 






In a dried, round-bottom flask equipped with a stir bar, and under nitrogen atmosphere, Fmoc-
(4F)Tyrosine-OH (0.100 g, 0.194 mmol) was dissolved in 5 mL of dichloromethane. To this, N,N’-
dicyclohexylcarbodiimide (0.025 mL, 0.162 mmol), HOBT (0.021 g, 0.162 mmol), and DIEA 
(0.057 mL, 0.324 mmol) were added at 0°C and the reaction mixture was allowed to stir for 45 
minutes before adding benzylamine (0.017 mL, 0.162 mmol). The reaction was allowed to stir 
overnight for 18 hours. The solvent was removed under reduced pressure and the resulting 
crude product was solubilized in ethyl acetate (50 mL) and washed with water (1 x 50 mL) 
followed by a wash with a brine solution (1 x 50 mL). The resulting organic layer was dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to afford the 
crude allyl protected product, which was purified via automated silica gel chromatography 
(Linear gradient of 7  60% ethyl acetate in hexanes) to yield the allyl protected intermediate 
product as a white crystalline solid (0.060 g, 52.3% yield). Removal of the allyl protecting groups 
subsequently followed, as the allyl protected intermediate (0.050 g, 0.085 mmol) was dissolved 
in 5 mL of dichloromethane. To this, tetrakis(triphenylphosphine)palladium(0) (0.005 g, 0.004 
mmol) and phenylsilane (0.021 mL, 0.17 mmol) were added and the reaction was allowed to stir 
overnight for 18 hours at room temperature. The reaction mixture was washed with a solution 
of 10% aqueous citrate (2 x 20 mL) and the resulting organic layer was dried with anhydrous 
MgSO4 and filtered. The solvent was removed under reduced pressure to afford the crude IV-
sms-89 product which was purified via automated silica gel chromatography (Linear gradient of 
0  10% methanol in dichloromethane) as well as by reverse-phase chromatography (linear 
gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield IV-sms-89 as a crystalline 
solid (21.1 mg, 44.0% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 8.44 (t, 
J = 5.5 Hz, 1H), 7.89 – 7.81 (m, 2H), 7.77 – 7.70 (m, 1H), 7.68 – 7.61 (m, 2H), 7.38 (t, J = 7.7 Hz, 
2H), 7.22 (ddd, J = 20.5, 14.3, 7.3 Hz, 3H), 7.11 – 7.04 (m, 2H), 4.32 – 4.07 (m, 6H), 3.06 (dd, J = 
14.2, 7.5 Hz, 1H), 2.84 (dd, J = 13.8, 7.5 Hz, 1H), contains solvent peaks. 19F NMR (400 MHz, 












In a dried, round-bottomed flask equipped with a stir bar, and under nitrogen atmosphere, Boc-
(4F)Tyrosine-OH (prepared via methods described in Wang, et al.1 0.500 g, 1.27 mmol) was 
solubilized in 10 mL of dichloromethane. To this, N,N’-dicyclohexylcarbodiimide (0.17 mL, 1.06 
mmol), HOBT (0.143 g, 1.06 mmol), and DIEA (0.37 mL, 2.12 mmol) were added at 0°C and the 
reaction mixture was allowed to stir for 45 minutes before adding benzylamine (0.116 mL, 1.06 
mmol). The reaction was allowed to stir overnight for 18 hours. The organics were removed 
under reduced pressure and the resulting crude product was solubilized in ethyl acetate (50 mL) 
and washed with water (1 x 50 mL) followed by a wash with a brine solution (1 x 50 mL). The 
resulting organic layer was dried over anhydrous MgSO4 and filtered. The solvent was removed 
under reduced pressure to afford the crude allyl protected product, which was purified via 
automated silica gel chromatography (Linear gradient of 7  60% ethyl acetate in hexanes) to 
yield the allyl protected intermediate product as a white crystalline solid (0.440 g, 72% yield). 
The Boc- and allyl protected intermediate (0.410 g, 0.850 mmol) was immediately solubilized in 
10 mL HCl (4N in dioxanes) and allowed to stir at room temperature for 4 hours to remove the 
Boc-protecting group. The reaction was concentrated under reduced pressure to dryness to 
yield the free amine and allyl protected intermediate as the HCl salt, a tan crystalline solid 
(0.360 g, 100% yield). This intermediate (0.047 mg, 0.123 mmol) was solubilized in 4 mL of 
dichloromethane. To this, diisopropylamine (0.090 mL, 0.492 mmol) and phenylisocyanate 
(0.017 mL, 0.148 mmol) were added and the reaction was allowed to stir overnight at room 
temperature. The organics were removed under reduced pressure and the resulting crude 
product was dissolved in ethyl acetate (50 mL) and washed with water (1 x 50 mL) followed by a 
wash with a brine solution (1 x 50 mL). The resulting organic layer was dried over anhydrous 
MgSO4 and filtered. The solvent was removed under reduced pressure to yield the crude allyl 
protected intermediate which was purified via automated silica gel chromatography (Linear 
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gradient of 0  10% methanol in dichloromethane) to afford the allyl protected intermediate 
(0.055 g, 88.6%). Removal of the allyl protecting groups subsequently followed, as the allyl 
protected intermediate (0.055 g, 0.109 mmol) was dissolved in 5 mL of dichloromethane. To 
this, tetrakis(triphenylphosphine)palladium(0) (0.006 g, 0.005 mmol) and phenylsilane (0.027 
mL, 0.22 mmol) were added and the reaction was allowed to stir overnight for 18 hours at 
room temperature. The reaction mixture was washed with a solution of 10% aqueous citrate (2 
x 20 mL) and the resulting organic layer was dried with anhydrous MgSO4 and filtered. The 
solvent was removed under reduced pressure to afford the crude IV-sms-89 product which was 
purified via automated silica gel chromatography (Linear gradient of 0  10% methanol in 
dichloromethane) as well as by reverse-phase chromatography (linear gradient of 5  95% 
CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield IV-sms-109 as a crystalline solid (2.9 mg, 6.0% 
yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 11.23 (s, 1H), 8.68 (d, J = 10.1 Hz, 2H), 7.07 
– 7.02 (m, 6H), 6.84 (d, J = 7.6 Hz, 2H), 6.44 (d, J = 9.5 Hz, 2H), 4.51 (d, J = 7.6 Hz, 1H), 4.21 (s, 
1H), 3.10 – 2.83 (m, 2H), contains solvent peaks.19F NMR (400 MHz, DMSO-d6) δ,  -144.91, -




Into a plastic, microwave peptide vessel, Rink Amide resin (340 mg, 0.160 mmol) was added 
and swollen with n-methyl-2-pyrrolidone (7 mL). The vessel was placed on a shake plate for 1 
hour at room temperature. Following this period, the solvent in the vessel was evacuated and 
to it, deprotection solution (7 mL, 20% piperidine, 0.15 M HOBT in NMP) was added. Again, the 
vessel was placed on a shake plate for 1 hour at room temperature and subsequently the 
solvent was evacuated and the beads were washed with NMP (3 x 10 mL). The resin beads were 
evaluated for complete Fmoc deprotection through the use of the Kaiser test.2 The resin beads 
were washed with DCM (3 x 5 mL) and dried.  A solution of Fmoc-(4F)tyrosine-OH (400 mg, 
0.780 mmol) and HBTU (296 mg, 0.780 mmol) and activator solution (10% Diisopropyl ethyl 
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amine in NMP, 4 mL) was prepared and added to the vessel containing the deprotected rink 
amide resin beads. The vessel was allowed to shake at room temperature overnight. Upon 
solvent evacuation and the washing of the beads (NMP, 3 x 10 mL), the resin beads were 
evacuated with the Kaiser test to insure complete coupling of the amino acid to the resin beads. 
Removal of the allyl protecting groups subsequently followed. To the vessel containing the resin 
beads, tetrakis(triphenylphosphine)palladium(0) (0.037 g, 0.032 mmol) and 1.3-
dimethylbarbituric acid (0.100 g, 0.640 mmol) were added and the reaction was allowed to stir 
overnight for 18 hours at room temperature. The resin beads were washed with 
dichloromethane (3 x 10 mL) and dried. Compound IV-sms-93 was separated from resin using 
cleavage conditions (trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropylsilane 0.1 mL) for 1 
hour with intermittent stirring. The resulting solution was filtered, collected and the solvent 
was removed under reduced pressure. The resulting oil was purified via reverse-phase 
chromatography (linear gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield 
IV-sms-93 as a white crystalline solid (5.3 mg, 7.3% yield). Spectral data. 1H NMR (400 MHz, 
DMSO-d6) δ 11.39 – 11.13 (m, 1H), 8.23 (s, 1H), 7.84 (d, J = 7.8 Hz, 2H), 7.68 – 7.46 (m, 2H), 7.31 
(dt, J = 31.9, 7.6 Hz, 3H), 7.12 (s, 1H), 5.28 (s, 1H), 4.29 – 4.05 (m, 3H), 3.69 (s, 1H), 3.29 (s, 4H), 




Prepared as previously described for compound IV-sms-93, the Fmoc-(4F)Tyrosine-OH was 
appended to Rink amide resin. The Fmoc protecting group was removed by adding 7 mL of 
deprotection solution (20% piperidine, 0.15 M HOBt in NMP) to the beads and allowing the 
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vessel to shake for 1 hour at room temperature. Subsequently, the solvent was evacuated, the 
beads were washed with NMP (3 x 10 mL), and the beads were evaluated for complete Fmoc 
removal through the use of the Kaiser test. To the vessel containing the Fmoc deprotected 
(4F)tyrosine resin beads, a solution of phenylisocyanate (5% in 4 mL of 10% 
diisopropylethylamine in NMP) was added and allowed to shake at room temperature 
overnight. The vessel was then evacuated, washed with NMP (3 x 5 mL) and evaluated by Kaiser 
test to ensure complete coupling of the phenylisocyanate. Removal of the allyl protecting 
groups subsequently followed. To the vessel containing the resin beads, 
tetrakis(triphenylphosphine)palladium(0) (0.037 g, 0.032 mmol) and 1.3-dimethylbarbituric acid 
(0.100 g, 0.640 mmol) were added and the reaction was allowed to stir overnight for 18 hours 
at room temperature. The resin beads were washed with dichloromethane (3 x 10 mL) and 
dried. Compound V-sms-57 was separated from resin using cleavage conditions (trifluoroacetic 
acid 3.8 mL, water 0.1 mL, triisopropylsilane 0.1 mL) for 1 hour with intermittent stirring. The 
resulting solution was filtered, collected and the solvent was removed under reduced pressure. 
The resulting oil was purified via reverse-phase chromatography (linear gradient of 5  95% 
CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield V-sms-57 as a crystalline solid (2.6 mg, 4.4% 
yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) 
1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, 
1H), 8.66 (s, 1H), 7.62 (s, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.23 – 7.11 (m, 3H), 6.84 (t, J = 7.3 Hz, 1H), 
6.32 (d, J = 8.2 Hz, 1H), 4.41 (t, J = 6.8 Hz, 1H), 3.42 (s, 1H), 3.05 – 2.82 (m, 2H), contains solvent 






Prepared as previously described for compounds IV-sms-93 and V-sms-57, the Fmoc-
(4F)Tyrosine-OH was appended to Rink amide resin. The Fmoc protecting group was removed 
by adding 7 mL of deprotection solution (20% piperidine, 0.15 M HOBt in NMP) to the beads 
and allowing the vessel to shake for 1 hour at room temperature. Subsequently, the solvent 
was evacuated, the beads were washed with NMP (3 x 10 mL), and the beads were evaluated 
for complete Fmoc removal through the use of the Kaiser test. To the vessel containing the 
Fmoc deprotected (4F)tyrosine resin beads, a solution of (3F)-phenylisocyanate (5% in 4 mL of 
10% diisopropylethylamine in NMP) was added and allowed to shake at room temperature 
overnight. The vessel was then evacuated, washed with NMP (3 x 5 mL) and evaluated by Kaiser 
test to ensure complete coupling of the phenylisocyanate. Removal of the allyl protecting 
groups subsequently followed. To the vessel containing the resin beads, 
tetrakis(triphenylphosphine)palladium(0) (0.037 g, 0.032 mmol) and 1.3-dimethylbarbituric acid 
(0.100 g, 0.640 mmol) were added and the reaction was allowed to stir overnight for 18 hours 
at room temperature. The resin beads were washed with dichloromethane (3 x 10 mL) and 
dried. Compound V-sms-174 was separated from resin using cleavage conditions 
(trifluoroacetic acid 3.8 mL, water 0.1 mL, triisopropylsilane 0.1 mL) for 1 hour with intermittent 
stirring. The resulting solution was filtered, collected and the solvent was removed under 
reduced pressure. The resulting oil was purified via reverse-phase chromatography (linear 
gradient of 5  95% CH3CN (0.1% HOAc) in H2O (0.1% HOAc)) to yield V-sms-174 as a 
crystalline solid (1.2 mg, 1.9% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) 
1H NMR (400 
MHz, DMSO-d6) δ δ 11.19 (s, 1H), 8.91 (s, 1H), 7.64 (s, 1H), 7.43 – 7.26 (m, 1H), 7.24 – 7.11 (m, 
1H), 6.89 (d, J = 8.3 Hz, 1H), 6.66 (t, J = 8.6 Hz, 1H), 6.39 (d, J = 8.1 Hz, 1H), 5.28 (s, 1H), 4.41 (q, J 
= 7.0 Hz, 1H), 3.07 – 2.80 (m, 1H), contains solvent peaks.19F NMR (400 MHz, DMSO-d6) δ  -





























































































































































B.4: Biochemical Characterization 
General procedure for determination of inhibitor Ki. A continuous fluorescence assay
3 was 
used to determine Ki. Reaction volumes of 100 µL were used in 96-well plates. 85 µL of enzyme 
in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution (final 
concentrations typically 1000, 500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9 and 0 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)3 solution 
(1.8 mM in DMSO) was added. The reaction was initiated with 10 µL of ATP (10 mM in water), 
and reaction progress was immediately monitored at 405 nm (ex. 340 nm) for 10 minutes. 
Reactions had final concentrations of 30 nM enzyme, 45 µM peptide substrate, 1000 µM ATP, 
100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100. The initial rate 
data collected was used for determination of Ki values. For Ki determination, the kinetic values 
were obtained directly from nonlinear regression of substrate-velocity curves in the presence of 
various concentrations of the inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – 
LogEC50), X = log(concentration) and Y = binding; was used in the nonlinear regression. 
 
Analytical data for c-Src Kinase Domain Ki determination. Each inhibitor Ki value was 
determined using at least four independent experiments, a representative inhibition curve is 
shown. 
 












































Average IC50: 131.2 ± 22.3 μM 
 












































Average IC50: 129.2 ± 24.6 μM 
 
 


























































Analytical data for c-Src T338M Ki determination. Each inhibitor Ki value was determined using 



































Analytical data for c-Src 3D Ki determination. Each inhibitor Ki value was determined using at 






































Analytical data for c-Abl Ki determination. Each inhibitor Ki value was determined using at least 
four independent experiments, a representative inhibition curve is shown 
 
 



































Analytical data for c-Hck Ki determination. Each inhibitor Ki value was determined using at 
least four independent experiments, a representative inhibition curve is shown. 
 
 
































Analytical data for c-Src Kinase domain Ki determination at high [ATP] (5 mM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 
 

































Analytical data for c-Src Kinase domain Ki determination at low [ATP] (100 μM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 
 
 
































Analytical data for c-Src Kinase domain Ki determination at high [substrate] (500 μM final 
concentration, 1 mM ATP concentration). Each inhibitor Ki value was determined using at least 
four independent experiments; a representative inhibition curve is shown. 
 
 
































General procedure for ATP Lineweaver-Burk analysis of inhibitor. A continuous fluorescence 
assay3 was used to determine KM. Reaction volumes of 100 µL were used in 96-well plates. 85 
µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution 
(fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was then added. 2.5 µL 
of a substrate peptide (“compound 3” as described in Wang et al)3 solution (1.8 mM in DMSO) 
was added. The reaction was initiated with 10 µL of ATP (Two-fold dilutions, final 
concentrations: 5mM  0 in water), and reaction progress was immediately monitored at 405 
nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 µM 
peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-
100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of ATP. The equation Y = 
(Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 
used in the nonlinear regression.  
 
Analytical data for c-Src Kinase Domain ATP Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
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General procedure for Substrate Lineweaver-Burk analysis of inhibitor. A continuous 
fluorescence assay3 was used to determine KM. Reaction volumes of 100 µL were used in 96-
well plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)3 solution 
(Final concentrations: 500 µM  0 in DMSO) was added. The reaction was initiated with 10 µL 
of ATP (Final concentration 1 mM in water), and reaction progress was immediately monitored 
at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 
µM peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton 
X-100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of substrate. The equation Y 
= (Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 
used in the nonlinear regression.  
 
Analytical data for c-Src Kinase Domain Substrate Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
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Supplemental Information for Chapter 4 
 
C.1: General Synthetic Methods Unless otherwise noted, all reagents were obtained from 
commercially available sources and used without further purification. All 1H and 13C NMR 
spectra were measured with a Varian 400 MHz spectrometer. Samples were taken in CDCl3 or 
DMSO-d6, spectra were referenced to chloroform peak. High resolution mass spectrometry 
(HRMS) was carried out by the University of Michigan Mass Spectrometry Facility (J. Windak, 
Director). 
C.2: Synthesis of Compounds  
Compounds [1], [1d], [1e], [1f], [1g]: 
 
These commercially available compounds were purchased from Maybridge Chemical, a part of 





Synthesis of compound [1a] 
 
In a dried, round-bottom flask equipped with a stir bar, and under nitrogen atmosphere, 5-
chlorobenzo[b]thiophene-3-carboxylic acid [1] (0.100 g, 0.472 mmol) was dissolved in 3 mL of 
dichloromethane. To this, oxalyl chloride (0.060 mL, 0.66 mmol) was added slowly, drop-wise. 
Following this, one drop of dimethylformamide was added. The reaction was allowed to stir at 
room temperature for thirty minutes at which point, the solvent was concentrated to yield the 
crude oil intermediate which was immediately used without further purification and dissolved 
in 2 mL of dichloromethane. To this, diisopropylethylamine (0.12 mL, 0.742 mmol) and aniline 
(0.033 mL, 0.362 mmol) were added at 0°C. The reaction was allowed to warm to room 
temperature overnight. The solvent was removed under reduced pressure and the resulting 
crude product was solubilized in ethyl acetate (50 mL) and washed with water (1 x 50 mL) 
followed by a wash with a brine solution (1 x 50 mL). The resulting organic layer was dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to afford the 
crude product, which was purified via automated silica gel chromatography (Linear gradient of 
7  100% ethyl acetate in hexanes) to yield compound [1a] as a yellow crystalline solid (117 
mg, 94% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.68 (s, 1H), 8.42 (s, 
1H), 8.10 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.46 (dd, J = 8.6, 2.4 Hz, 2H), 7.34 (t, J = 8.0 
Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H). 13C NMR (400 MHz, DMSO-d6) δ 161.82, 139.30, 138.91, 138.43, 
134.77, 130.70, 130.47, 129.41, 129.10, 125.53, 125.03, 124.15, 124.01, 120.70. HRMS-ESI 
(m/z): [M+H]+ calcd for C15H10ClNOS 288.0244; found 288.0239. 
Synthesis of compound [1b]: 
 
In a dried, round-bottom flask equipped with a stir bar, and under nitrogen atmosphere, 5-
chlorobenzo[b]thiophene-3-carboxylic acid [1] (0.100 g, 0.472 mmol) was dissolved in 5 mL of 
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dichloromethane. To this, HBTU (0.197 g, 0.519 mmol), HOBT (0.070 g, 0.519 mmol), 
diisopropylethylamine (0.090 mL, 0.519 mmol), and benzylamine (0.052 mL, 0.472 mmol) were 
added at 0°C. The reaction was allowed to warm to room temperature overnight. The organics 
were removed under reduced pressure and the resulting crude product was solubilized in ethyl 
acetate (50 mL) and washed with water (1 x 50 mL) followed by a wash with a brine solution (1 
x 50 mL). The resulting organic layer was dried over anhydrous MgSO4 and filtered. The solvent 
was removed under reduced pressure to afford the crude product, which was purified via 
automated silica gel chromatography (Linear gradient of 7  100% ethyl acetate in hexanes) to 
yield compound [1a] as a crystalline solid (140 mg, 98% yield). Spectral data. 1H NMR (400 MHz, 
DMSO-d6) δ 9.07 (t, J = 5.9 Hz, 1H), 8.51 (d, J = 10.0 Hz, 2H), 8.05 (d, J = 8.6 Hz, 1H), 7.42 (dd, J = 
8.7, 2.3 Hz, 1H), 7.31 (d, J = 6.9 Hz, 4H), 7.22 (d, J = 6.8 Hz, 1H), 4.47 (d, J = 5.9 Hz, 2H). 13C NMR 
(400 MHz, DMSO-d6) δ 163.08, 139.90, 139.04, 138.45, 133.70, 130.55, 130.16, 128.75, 127.71, 
127.24, 125.35, 124.90, 124.23, 42.70. HRMS-ESI (m/z): [M+H]+ calcd for C16H12ClNOS 302.0401; 
found 302.0398. 
 Synthesis of compound [1c] 
 
In a dried, round-bottom flask equipped with a stir bar, and under nitrogen atmosphere, 5-
chlorobenzo[b]thiophene-3-carboxylic acid [1] (0.100 g, 0.472 mmol) was dissolved in 3 mL of 
dimethylformamide. To this, iodomethane (0.040 mL, 0.705 mmol), potassium carbonate (0.098 
mL, 0.709 mmol) were added and was allowed to stir overnight at room temperature. The 
reaction was quenched with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The 
resulting organic layer was washed with a saturated sodium bicarbonate solution (1 x 50 mL) 
followed by a wash with a brine solution (1 x 50 mL). The resulting organic layer was dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to afford the 
crude product, which was purified via automated silica gel chromatography (Linear gradient of 
7  100% ethyl acetate in hexanes) to yield compound [1a] as a white crystalline solid (70 mg, 
66% yield). Spectral data. 1H NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.33 (d, J = 2.3 Hz, 1H), 
8.05 (d, J = 8.7 Hz, 1H), 7.50 – 7.33 (m, 1H), 3.84 (s, 3H). 13C NMR (100 MHz, dmso) δ 162.59, 
140.92, 138.55, 137.88, 131.22, 129.69, 125.56, 125.17, 123.44, 52.28. HRMS-ESI (m/z): [M+H]+ 































































C.4: Biochemical Characterization 
General procedure for determination of inhibitor Ki. A continuous fluorescence assay
2 was 
used to determine Ki. Reaction volumes of 100 µL were used in 96-well plates. 85 µL of enzyme 
in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution (final 
concentrations typically 1000, 500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9 and 0 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)2 solution 
(1.8 mM in DMSO) was added. The reaction was initiated with 10 µL of ATP (10 mM in water), 
and reaction progress was immediately monitored at 405 nm (ex. 340 nm) for 10 minutes. 
Reactions had final concentrations of 30 nM enzyme, 45 µM peptide substrate, 1000 µM ATP, 
100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100. The initial rate 
data collected was used for determination of Ki values. For Ki determination, the kinetic values 
were obtained directly from nonlinear regression of substrate-velocity curves in the presence of 
various concentrations of the inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – 
LogEC50), X = log(concentration) and Y = binding; was used in the nonlinear regression. 
 
Analytical data for c-Src Kinase Domain Ki determination. Each inhibitor Ki value was 




















































Average IC50: > 125 μM 
 
 



















































Average IC50: > 125 μM 
 
 












































Average IC50: > 125 μM 
 















































Average IC50: > 125 μM 
 
 
Analytical data for c-Abl Kinase Domain Ki determination. Each inhibitor Ki value was 
determined using nine independent experiments, a representative inhibition curve is shown. 
 

























Average IC50: 195.0 ± 84.9 μM 
196 
 
Analytical data for c-Hck Kinase Domain Ki determination. Each inhibitor Ki value was 
determined using six independent experiments, a representative inhibition curve is shown. 
 


























Average IC50: > 125 μM 
Analytical data for c-Src T338M Kinase Domain Ki determination. Each inhibitor Ki value was 
determined using four independent experiments, a representative inhibition curve is shown. 
 

























Average IC50: 7.93 ± 2.23 μM 
197 
 
Analytical data for c-Src Kinase domain Ki determination at high [ATP] (5 mM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 
 

























Average IC50: 7.72 ± 1.47 μM 
Analytical data for c-Src Kinase domain Ki determination at low [ATP] (100 μM final 
concentration, 45 μM substrate concentration). Each inhibitor Ki value was determined using 
at least four independent experiments; a representative inhibition curve is shown. 
 

























Average IC50: 9.01 ± 3.38 μM 
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General procedure for ATP Lineweaver-Burk analysis of inhibitor. A continuous fluorescence 
assay2 was used to determine KM. Reaction volumes of 100 µL were used in 96-well plates. 85 
µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate inhibitor dilution 
(fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was then added. 2.5 µL 
of a substrate peptide (“compound 3” as described in Wang et al)2 solution (1.8 mM in DMSO) 
was added. The reaction was initiated with 10 µL of ATP (Two-fold dilutions, final 
concentrations: 5mM  0 in water), and reaction progress was immediately monitored at 405 
nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 µM 
peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-
100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of ATP. The equation Y = 
(Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 
used in the nonlinear regression.  
 
Analytical data for c-Src Kinase Domain ATP Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
K M  fo r  M a y b r id g e  C o m p o u n d  [1 ]  v s . A T P
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General procedure for Substrate Lineweaver-Burk analysis of inhibitor. A continuous 
fluorescence assay2 was used to determine KM. Reaction volumes of 100 µL were used in 96-
well plates. 85 µL of enzyme in buffer was added to each well. 2.5 µL of the appropriate 
inhibitor dilution (fixed concentrations, typically 0, 35, 50, 70, 100, or 140 µM in DMSO) was 
then added. 2.5 µL of a substrate peptide (“compound 3” as described in Wang et al)2 solution 
(Final concentrations: 500 µM  0 in DMSO) was added. The reaction was initiated with 10 µL 
of ATP (Final concentration 1 mM in water), and reaction progress was immediately monitored 
at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 45 
µM peptide substrate, 100 µM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton 
X-100. The initial rate data collected was used for determination of KM values. For KM 
determination, the kinetic values were obtained directly from nonlinear regression of 
substrate-velocity curves in the presence of various concentrations of substrate. The equation Y 
= (Vmax * X)/(Km + X), X = substrate concentration (µM) and Y = enzyme velocity (RFU/s); was 
used in the nonlinear regression.  
 
Analytical data for c-Src Kinase Domain Substrate Lineweaver-Burk analysis of inhibitor. Each 
inhibitor KM value was determined using at least 4 independent experiments; a representative 
KM curve is shown. 
K M  fo r  M a y b r id g e  C o m p o u n d  [1 ]  v s .  S u b s tr a te
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C.5: Cancer cell growth inhibition assays 
General procedure:  
1. Cell culture and seeding:  Cells are dispersed from flasks and collected by centrifugation 
(125xg for 5 minutes at room temperature). An aliquot of the resuspended cells is mixed 
with trypan blue solution and the cell number is quantified using a hemacytometer. In 
general, depending on the growth rate of the untreated cells, the cells will be plated at 
5.0 – 7.5 x 103 cells per well. 100 µL of the cell mixture will be added to each well so the 
concentration should be 10X the cells per well in cells per mL. The cells are plated into 
sterile, clear bottom 96 well plates and cultured under normal growth conditions 
overnight prior to dosing with compound. 
2. Dosing: The 100% DMSO compound stocks need to be prepared to 100X the final 
concentration that is desired in the assay. 3 µL of the DMSO stock solution is then added 
to 297 µL of the cell growth media to give a DMSO concentration of 1%. The cell media 
is removed by aspiration for adherent cells and replaced with 100 µL per well of the cell 
growth media containing the compound. In general each compound concentration is 
dosed in triplicate wells. The plates are returned to normal culture conditions for 24 – 
72 hours.  
3. Assay: After the required incubation period the plates are removed from the incubator 
and 10 µL per well of WST-1 reagent is added. The plates are returned to the incubator 
and the color change is visually monitored for 0.5 – 2 hours. When sufficient color 
change has occurred the plates are shaken on a plate shaker for 60 seconds and read in 
the appropriate plate reader.  
4. Data Analysis: The reference absorbance reading is subtracted from the formazan 
absorbance and the data is plotted as a percentage of the vehicle (1% DMSO alone). 
Data analysis and curve fitting was performed using Graphpad Prism. For each cell line, 
there were n = 3 data points for each concentration. Each dose response curve was 









Maybridge Compound [1] and SK-BR-3 cell line: 
C e ll P r o life ra t io n  S tu d y : S K -B R -3  c e lls  a n d  [1 c ]
7 2  h o u r  e x p o s u r e




































 (1) Maybridge; 2013, http://www.maybridge.com/images/pdfs/ro3frag.pdf. 
 (2) Wang, Q.; Cahill, S. M.; Blumenstein, M.; Lawrence, D. S. J. Am. Chem. Soc. 2006, 




Supplemental Plots for Compounds of Interest 
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